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I. INTRODUCTION
Artificial intelligence is entering medical practice. The combination of medical big data and machine learning techniques allows developers to create AI usable in medical contexts — also called “blackbox medicine” due to its inherent opacity — that can help improve
human health and health care. Only a few years ago, black-box medicine seemed far from real-world use. Today, there are already FDAapproved devices that use AI to diagnose diabetic retinopathy or to
flag radiologic images for further study.1 Hospitals have used AI to
help develop care pathways for increasingly specified groups of patients. Future uses are multiplying.
But there is a problem lurking in the development of AI in medicine.2 A key promise of medical AI is its ability to democratize medical expertise, allowing providers of all sorts to give care that
otherwise might be beyond their capacity. 3 Medical AI is typically
trained in high-resource settings: academic medical centers or state-

1. See infra Section III.C.1.
2. Actually, there are lots of problems, including how to set proper incentives, how to
regulate for safety and efficacy, how to use the tort system to encourage providers and hospitals to adopt the best medical AI products, challenges to the doctor-patient relationship,
and questions of diminishing human expertise. For an initial overview on those problems
and an introduction to medical AI generally, see W. Nicholson Price II, Black-Box Medicine, 28 HARV. J.L. & TECH. 419 (2015) [hereinafter Price, Black-Box Medicine] (introducing medical AI and canvassing several issues). This Article is focused on a different
problem.
3. See, e.g., Victoria J. Mar &. Peter H. Soyer, Artificial Intelligence for Melanoma Diagnosis: How Can We Deliver on the Promise?, 29 ANNALS ONCOLOGY 1625, 1625 (2018)
(“[A]rtificial intelligence (AI) promises a more standardised level of diagnostic accuracy,
such that all people, regardless of where they live or which doctor they see, will be able to
access reliable diagnostic assessment.”).
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of-the-art hospitals or hospital systems. 4 These sites typically have
well-trained, experienced practitioners and are most likely to have
high-quality data collection systems; training medical AI in these systems makes intuitive sense. Democratizing medical expertise, though,
requires deploying that medical AI in low-resource settings like community hospitals, community health centers, practitioners’ offices, or
rural health centers in less-developed countries.5 This translation runs
into a problem: low-resource contexts have different patient populations and different resources available for treatment than highresource contexts, and disparities in available data make it hard for AI
to account for those differences.
The translational disconnect between high-resource training environments and low-resource deployment environments will likely result in predictable decreases in the quality of algorithmic
recommendations for care, limiting the promise of medical AI to actually democratize excellence. To take a simple example: at Memorial
Sloan Kettering, one of the best cancer centers in the world, it may
well make sense to give a patient a cocktail of powerful chemotherapeutics with potentially fatal side effects, since trained oncology nurses and other specialists are available to monitor problems and
intervene if things go wrong. In a community hospital without those
safeguards, though, it may be a better call to administer less drastic
remedies, avoiding the chance of catastrophic failure. That danger is
even more pronounced in even lower-resource settings, such as rural
areas of less-developed countries. But medical AI trained only on data
from Memorial Sloan Kettering would have no way of taking that
resource constraint into account and would provide a poor recommendation to providers in those lower-resource settings.6
Contextual bias is an under-addressed kind of bias in the legal AI
literature.7 Rather than the bias arising from problems in the underlying data, such as when policing algorithms end up silently replicating
4. See MICHAEL E. MATHENY ET AL., NAT’L ACAD. OF MED., AI & MACHINE LEARNING
IN HEALTH CARE, Section 2.E.2 (forthcoming 2019) (manuscript at 46) (on file with author)
(noting that “[i]n the United States, MIT, Stanford and Carnegie Mellon pioneered AI research in the 1960s, and these, and many others, continue to do so today”).
5. I focus in this Article on medical AI that is used in health-care settings, not consumerfocused devices, though some of the same issues arise in the latter context as well.
6. It is not impossible to take resource constraints into account in AI decision-making,
but, as the rest of this Article demonstrates, doing so is complicated and requires more data
than are available from just high-resource settings.
7. For a “whirlwind tour” of AI bias issues, see Karen Hao, This Is How AI Bias Really
Happens and Why It’s So Hard to Fix, MIT TECH. REV. (Feb. 4, 2019),
https://www.technologyreview.com/s/612876/this-is-how-ai-bias-really-happensand-whyits-so-hard-to-fix [https://perma.cc/XNG3-XWY7]. In the computer science literature, see,
for example, Adarsh Subbaswamy & Suchi Saria, Counterfactual Normalization: Proactively Addressing Dataset Shift and Improving Reliability Using Causal Mechanisms, ARXIV,
Aug. 9, 2018, https://arxiv.org/pdf/1808.03253v1.pdf [https://perma.cc/CCZ5-W6JP] (revised from print version).
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racial bias in underlying arrest patterns and the data they generate8 or
when health algorithms accurately mirror racial or gender biases already present in health care,9 this bias arises in the process of translating algorithms from one context to another. The care provided in
high-resource contexts may be superb and untinged by problematic
human bias of any kind, and this bias would still arise.10
I do not mean to suggest that AI developers are unaware of the
challenges of translating AI from one context to another, or the differences between high- and low-resource contexts. The technique of
“transfer learning,” for instance, focuses on taking insights from one
environment and using them in another.11 And some work, especially
nonprofit work in the global health space, focuses intently on developing robust AI especially for deployment in low-resource contexts in
less-developed countries. 12 But this Article places the dynamics of
cross-context translation into a legal context where, particularly in the
United States, incentives actively promote problematic development
patterns; it also suggests why the data most useful to address problems
of contextual bias are least likely to be available.
This Article analyzes how medical AI can run into problems
through an otherwise reasonable process of development and deployment. It proceeds in four Parts. Part II briefly describes the promise of
artificial intelligence in medicine, focusing on the idea of democratizing medical expertise. Part III explores the incentives for developing
8. See, e.g., Andrew D. Selbst, Disparate Impact in Big Data Policing, 52 GA. L. REV.
109, 119–43 (2018).
9. See, e.g., Ziad Obermeyer et al., Dissecting Racial Bias in an Algorithm Used to Manage the Health of Populations, 366 SCI. 447, 447 (2019) (finding that a widely used algorithm used to predict patient risk was biased based on race because the algorithm predicted
health care costs, and less is spent on African-American patients than comparable white
patients).
10. High-resource care may be biased. See, e.g., David A. Ansell & Edwin K. McDonald,
Bias, Black Lives, and Academic Medicine, 372 NEW ENG. J. MED. 1087, 1087–89 (2015).
But contextual bias can occur independently from any bias in the high-resource care on
which the training data are generated, as described in Parts IV and V.
11. See, e.g., Jenna Wiens et al., A Study in Transfer Learning: Leveraging Data from
Multiple Hospitals to Enhance Hospital-Specific Predictions, 21 J. AM. MED. INFORMATICS
ASS’N 699, 699 (2014) (examining the transfer of learning among three hospitals); Dianbo
Liu et al., FADL: Federated-Autonomous Deep Learning for Distributed Electronic Health
Record, ARXIV, Nov. 28, 2018, https://arxiv.org/pdf/1811.11400.pdf [https://perma.cc/
DHA6-R3ZV] (suggesting a federated network where generalized insights can be applied in
individual contexts); Awni Y. Hannun et al., Cardiologist-Level Arrhythmia Detection and
Classification in Ambulatory Electrocardiograms Using a Deep Neural Network, 25
NATURE MED. 65, 69 (2019) (noting need to calibrate algorithms to local populations).
12. See, e.g., Valentina Bellemo et al., Artificial Intelligence Using Deep Learning to
Screen for Referable and Vision-Threatening Diabetic Retinopathy in Africa: A Clinical
Validation Study, 1 LANCET DIGITAL HEALTH e35 (2019) (validating in Zambia a model
trained on diabetic patients from Singapore); ELEONORE PAUWELS, U.N. UNIV. CTR. FOR
POLICY RESEARCH, THE NEW GEOPOLITICS OF CONVERGING RISKS: THE UN AND
PREVENTION IN THE ERA OF AI 28 (2019), https://i.unu.edu/media/cpr.unu.edu/attachment/
3472/PauwelsAIGeopolitics.pdf [https://perma.cc/2Y7S-7JAP].
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medical AI in high-resource medical contexts. It explores how technological factors around data availability are buttressed by legal and
economic incentives to focus AI training on high-resource contexts.
Part IV, the heart of the paper, lays out the different types of errors that can arise when medical AI trained in high-resource contexts
is deployed in low-resource contexts. It notes problematic differences
in patient populations, differences in recommended treatments based
on the available resources of the medical environment, and systematic
influences on cost.
Part V addresses a question of scope: isn’t all medicine contextual? Treatments are developed and doctors are trained in one set of
contexts — often high-resource — and then care occurs in a wide array of different contexts. In one sense, medical AI embodies the same
type of contextual bias. But medical AI carries the illusory promise of
being different because it can theoretically take into account exactly
those contextual differences to tailor care and can learn from its own
performance. However, this safeguard fails if medical AI lacks data
from different contexts to adjust its recommendations. The resulting
contextual bias is especially insidious because medical AI is typically
opaque, hiding the negative effects that may result.
Part VI discusses potential solutions. It begins with two obvious
but flawed solutions. First, could we rely on human doctors “in the
loop” to provide common-sense checks on medical AI contextual bias
errors? Unfortunately, even assuming that doctors have the
knowledge, incentive, and willingness to correct AI errors — assumptions that may not be merited — in many low-resource situations
where AI can bring the most benefit, well-trained human providers
will simply not be present. Second, could we simply rely on labeling
to inform users of its limitations? I argue that labeling is unlikely to
solve the problem, since training-based labels are difficult to design,
likely to be ignored, and, if followed, would eviscerate much of the
promise of democratizing expertise. This Part suggests instead that a
better solution requires a combination of public investment in data
infrastructure and regulatory mandates of data showing that AI focuses well across different contexts. This combination would ameliorate
the problem of contextual translation and help ensure that medical AI
actually does provide benefits more broadly, rather than just to those
who can already access high-resource care.
Part VI also notes that while the problem of contextual bias needs
addressing, policymakers should not be misled by the Nirvana fallacy.13 Some forms of even imperfect medical AI promise substantial

13. See Harold Demsetz, Information and Efficiency: Another Viewpoint, 12 J.L. &
ECON. 1, 1 (1969) (defining the “nirvana approach” as seeking “to discover discrepancies
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benefit to underserved patients, and the field’s growth should not be
strangled while we await perfection.
Before proceeding, one caveat is in order. Medical AI is on the
cusp of entering practice, and a few specific examples of medical AI
are already available. But it is early yet, and some of the features key
to this discussion are largely in development, especially AI that recommends a particular treatment for a particular patient. The predicates
of the argument made here — medical AI, training in high-resource
contexts, differences in patient population and resources, and impact
of resources on treatment plans — are all already present. I argue that
their combination is likely to lead to problems in the process of contextual translation, barring action specifically taken to avoid those
problems. But I cannot yet point to instances where such problems
have happened, and it is possible that careful developers and regulators will ensure that they never do, even without explicit policy intervention.14 Nevertheless, the risk needs to be identified and brought to
the fore now. Medical AI is developing rapidly and will become increasingly embedded in medical practice; the problem of pervasively
biased treatment will be easier to avoid than to fix.

II. THE PROMISE OF BLACK-BOX MEDICINE
Medical AI promises big things. Big data and machine learning
can help health-care providers explore new biological relationships
and new methods of treatment, automate many low-level tasks that fill
providers’ days, and raise the general level of care by allowing many
types of providers to access expertise through the intermediary of
medical AI.15 Each of these possibilities can bring substantial changes
to the world of health care. This Part briefly describes the first two,
and then focuses in depth on the third, which the rest of this Article
addresses.
A. Advancing Medical Knowledge
Black-box medicine’s headline promise is to stretch the boundaries of medical care by uncovering and using new information about
between the ideal and the real” and finding “the real is inefficient” without comparing relevant choices between real institutional arrangements).
14. Cf. Jorge L. Contreras, The Anticommons at 20: Concerns for Research Continue,
361 SCI. 335, 336 (2018) (noting that concerns about innovation stagnation theorized by
Michael Heller and Rebecca Eisenberg twenty years earlier had not come to pass in part due
to community efforts to avoid them).
15. See generally W. Nicholson Price II, Artificial Intelligence in the Medical System:
Four Roles for Potential Transformation, 18 YALE J. HEALTH POL’Y L. & ETHICS, 21 YALE
J.L. & TECH., Special Issue 122 (2019). (describing these three roles and also noting the use
of AI in resource allocation).
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how humans work and how to care for them. Human biology is tremendously complex and our tools for understanding it are limited;
artificial intelligence promises to find and use complex underlying
relationships to improve care, discover new treatments, and advance
scientific hypotheses even if we don’t understand those underlying
relationships.16
Medical AI is already pushing boundaries. IBM’s Watson for
Drug Discovery used AI to identify genes likely to be associated with
Alzheimer’s disease and flagged them as potential targets for new
drugs.17 AI systems can similarly allow things we can’t do now; a
wearable device could predict the onset of stroke by analyzing a person’s gait18 or AI software could notice the onset of Parkinson’s disease by monitoring trembling of a computer mouse and the
characteristics of web searches.19 AI systems could also predict which
patients might react better to a particular treatment by noticing subtle
groupings among patients that are currently undetectable through
standard analysis.20 All of these possibilities promise to push past the
current frontiers of medical knowledge.
B. Automating the Routine
A second, more quotidian promise of medical AI is automating
medical drudgery. The problem here is that much of medical practice
consists of tasks that aren’t really about practicing medicine; instead,
they focus on paperwork and routine tasks that often don’t do much to
help patients and contribute to physician burnout. Providers are deluged with data searching and data entry tasks; one study found that
physicians spent almost half of their time on electronic health record
work and desk work, and only a quarter of their time seeing patients.21
16. See Price, Black-Box Medicine, supra note 2, at 434–37.
17. See, e.g., Nadine Bakkar et al., Artificial Intelligence in Neurodegenerative Disease
Research: Use of IBM Watson to Identify Additional RNA-Binding Proteins Altered in Amyotrophic Lateral Sclerosis, 135 ACTA NEUROPATHOLOGICA 227, 229 (2018) (describing
IBM Watson’s processing of the scientific literature to identify new genes linked to ALS).
18. See Fei Jiang et al., Artificial Intelligence in Healthcare: Past, Present, and Future, 2
STROKE & VASCULAR NEUROLOGY 230, 240 (2017).
19. See Ryen W. White et al., Detecting Neurodegenerative Disorders from Web Search
Signals, NATURE: NPJ DIGITAL MED., Apr. 23, 2018, at 1, 1.
20. Jiang et al., supra note 18, at 239–40 (noting proposed AI-based stroke treatment
models); id. at 241 (describing AI-based cancer treatment prediction). AI may also enhance
existing medical device usage. Charlotte A. Tschider, Deus ex Machina: Regulating Cybersecurity and Artificial Intelligence for Patients of the Future, 5 SAVANNAH L. REV. 177, 189
(2018) (describing the evolution of medical devices from self-executing, device-bound code
to AI and distributed infrastructure models).
21. Christine Sinsky et al., Allocation of Physician Time in Ambulatory Practice: A Time
and Motion Study in 4 Specialties, 165 ANNALS INTERNAL MED. 753, 753 (2016); see also
Ming Tai-Seale et al., Electronic Health Record Logs Indicate that Physicians Split Time
Evenly Between Seeing Patients and Desktop Medicine, 36 HEALTH AFF. 655, 655 (2017)
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Even in the examination room, physicians spent only about half of
their time interacting with patients — and about a third interacting
with electronic health records and desk work.22 The ability of AI to
automate at least some of this work could have a profound effect on
the provision of health care, potentially improving the doctor-patient
relationship23 and reducing the rate of provider burnout.24
Automation of routine tasks, though not as exciting as pushing
medical frontiers, could still change medical practice for the better.
Some action could happen on the front end: AI could automatically
identify and highlight the most relevant medical information from
patient medical records to reduce the time spent scrolling through records looking for information. 25 It could provide the most relevant
medical literature to doctors based on natural-language processing.26
And speech-recognition software based on AI could automatically
transcribe patient conversations and provider notes and fill out forms
afterward.27 Assuming eventual accuracy on the part of AI, such assistance could also reduce the rate of transcriptional errors and even improve privacy as details are read by machines rather than medical
scribes.

(finding that physicians “logged an average of 3.08 hours on office visits and 3.17 hours on
desktop medicine each day”).
22. See Sinsky et al., supra note 21, at 753.
23. Cf. Maria Alcocer Alkureishi et al., Impact of Electronic Medical Record Use on the
Patient–Doctor Relationship and Communication: A Systematic Review, 31 J. GEN.
INTERNAL MED. 548, 550–57 (2016) (evaluating many studies and finding both positive and
negative impacts of EHRs on patient-doctor relationships).
24. In a 2018 survey, “too many bureaucratic tasks” was the most commonly cited contributor to physician burnout. Carol Peckham, National Physician Burnout and Depression
Report 2018, MEDSCAPE (Jan. 17, 2018), https://www.medscape.com/slideshow/2018lifestyle-burnout-depression-6009235#13.
25. See Kory Kreimeyer et al., Natural Language Processing Systems for Capturing and
Standardizing Unstructured Clinical Information: A Systematic Review, 73 J. BIOMEDICAL
INFORMATICS 14, 14 (2017); cf. Theresa A. Koleck et al., Natural Language Processing of
Symptoms Documented in Free-Text Narratives of Electronic Health Records: A Systematic
Review, 26 J. AM. MED. INFORMATICS ASS’N 364, 365 (2019) (explaining that the previously manual process of extracting symptom information from patient records could be automated through natural language processing to reduce time spent by clinical experts).
26. Cf. Kreimeyer et al., supra note 25, at 15.
27. Id.; see also Linda Dawson et al., A Usability Framework for Speech Recognition
Technologies in Clinical Handover: A Pre-Implementation Study, 38 J. MED. SYS., June
2014, at 1, 1. Yet another potential use for medical AI comes in its use to analyze and direct
medical resources: assigning scarce resources to patients based on likelihood of aiding them,
improving workflow, or even finding ways to optimize medical billing. Cf. I. Glenn Cohen
et al., The Legal and Ethical Concerns That Arise from Using Complex Predictive Analytics
in Health Care, 33 HEALTH AFF. 1139, 1140 (2014). These interventions, focused less
directly on care encounters, are outside the scope of this work.
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C. Democratizing Expertise
Finally, medical AI promises to democratize medical expertise.
Today, there are tremendous differences in the quality and level of
care patients receive based on the context in which they receive that
care.28 This is reflected in everything from the availability of a specialist (e.g., whether a patient can see a board-certified ophthalmologist or dermatologist rather than relying on a primary care physician
for more complex care) to the type of practitioner involved (e.g., physician versus nurse practitioner) to the qualifications of the provider
(e.g., top-of-her-class with elite fellowships to less-exalted qualifications). 29 Medical AI promises to reduce this variation by “leveling
up” — allowing a much broader swath of providers to provide care at
the level of excellent specialists, which is what I mean by democratization of medical expertise. Medical AI is scalable in a way that human expertise simply is not; although gathering data, training
algorithms, and validating algorithmic performance are all hard and
expensive tasks,30 duplicating an existing algorithm for use in another
setting is much easier and cheaper than training new people for the
same tasks.31 It’s not free or easy — information infrastructure still
needs to be set up,32 and the data the algorithm will analyze need to be
properly collected and formatted on-site33 — but an algorithm is easier to copy than an oncologist.
This Section describes how AI can democratize different types of
medical expertise. It then considers where AI can bring expertise — a
span that ranges from other high-resource settings like mid-level hos28. See, e.g., John E. Wennberg, Unwarranted Variations in Healthcare Delivery: Implications for Academic Medical Centres, 325 BMJ 961, 962–63 (2002); DARTMOUTH ATLAS
PROJECT, https://www.dartmouthatlas.org [https://perma.cc/YA3A-5JCY] (cataloging regional differences in care).
29. I recognize that quality of care is not uni-dimensional; for a gastrointestinal problem,
a patient would likely rather see a novice nurse practitioner than an experienced neurosurgeon, and with good reason. Nevertheless, there are many situations for which the expertise
of a well-trained specialist can improve care.
30 . See W. Nicholson Price II, Big Data, Patents, and the Future of Medicine, 37
CARDOZO L. REV. 1401, 1411 (2016) [hereinafter Price, Big Data].
31. Such duplication is not costless, of course, and in some situations doing the transfer
right might actually be more expensive than home-growing a solution. See, e.g., JAMES E.
TCHENG ET AL., NAT’L ACAD. OF MED., OPTIMIZING STRATEGIES FOR CLINICAL DECISION
SUPPORT: SUMMARY OF A MEETING SERIES 28 (2017) (“While the creation of CDS [clinical
decision support] content in-house is an expensive and resource-intensive endeavor, sharing
CDS content, either with peers or through the licensing of vendor content, is presently perceived to be equally or more expensive; thus this duplication of effort at each site has persisted.”).
32. See W. Nicholson Price II, Risk and Resilience in Health Data Infrastructure, 16
COLO. TECH. L.J. 65, 71 (2017) [hereinafter Price, Risk and Resilience].
33. Further down the road, AI can help here too; natural language processing will make it
easier to accept unstructured data about patients rather than requiring data to be in a certain
format. See supra Section II.B.
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pitals to very low-resource settings like rural providers in lessdeveloped countries.
1. Diagnostics and Treatment Recommendations
AI can democratize different types of medical expertise. Though
medical expertise comes in many flavors, with many interconnections,
we can usefully consider two rough classes: diagnostics and treatment
recommendations.34
a. Diagnostics
Diagnosis is the process of figuring out what’s wrong with a patient. 35 If a patient comes in complaining of an exceptionally bad
headache, is she suffering from tension headache, a migraine, or a
subdural hematoma? One demands over-the-counter painkillers, another a large set of unpredictable medications, and the last an immediate trip to the emergency department to avoid death or severe brain
injury. Fans of the television series House will readily recognize the
recurrent problem of finding out what malady (or combination of
maladies) underlies a collection of symptoms. Diagnosis is hard
(though Dr. House makes it look easy); it depends on recognizing the
right symptoms and using them to identify underlying problems from
a vast realm of possibilities. Excellent diagnosticians, when available,
are tremendously valuable to medical care — but not everyone can be
an excellent diagnostician. Providers may reach incorrect diagnoses
because they never acquired the relevant medical knowledge, the
knowledge they acquired is outdated, they lack time to conduct the
relevant research, they suffer from heuristic biases such as recalling

34. Both of these forms of expertise can also be advanced by AI. See supra Section II.A.
This section focuses on their democratization. There are more things AI can do in medicine.
Prognostics, for instance, are an area of active development; it is good to be able to predict
what will happen to a patient, to know how long they might live, and who may become
sicker. Cf. Ziad Obermeyer & Ezekiel J. Emanuel, Predicting the Future — Big Data, Machine Learning, and Clinical Medicine, 375 NEW ENG. J. MED. 1216, 1217 (2016) (discussing machine learning and prognostics generally); Alvin Rajkomar et al., Scalable and
Accurate Deep Learning with Electronic Health Records, NATURE: NPJ DIGITAL MED., May
8, 2018, at 1, 1 (presenting a model with high accuracy predicting patient mortality, unplanned readmission, and prolonged length of stay). This Article focuses on diagnostics and
treatment recommendations as two possibilities for medical AI focused most closely on
direct patient care.
35. Diagnosis is not always entirely separable from treatment. In many circumstances,
the mere provision of a correct diagnosis can provide relief to patients who know more
about what is happening to them and can enable useful self-care. See, e.g., Sumi Sexton &
Robert Loflin III, The Relief of Getting a Diagnosis, 80 AM. FAM. PHYSICIAN 1223, 1223
(2009); see also racheldoesstuff, A Diagnosis, YOUTUBE (Nov. 17, 2017),
https://www.youtube.com/watch?v=uic_3vlI5BE [https://perma.cc/F4BS-U2LW].
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memorable rare diseases rather than common ones,36 or, most simply,
they are unfamiliar with the area of care. Artificial intelligence, based
largely on pattern recognition, can help democratize diagnostic expertise, allowing access to this expertise even when an excellent human
diagnostician is not available.37
EyeDiagnosis’s IDx-DR software for diabetic retinopathy is an
example of leveling-up that AI can bring to medical diagnosis.38 Diabetic retinopathy is a condition wherein diabetes causes loss of small
blood vessels in the retina; new blood vessels that grow to replace
them can cause vision problems.39 The current standard of care is for
patients with diabetes to visit an ophthalmologist yearly to check for
signs of retinopathy, so that treatment can begin before the retina
worsens. 40 But this requires regularly visiting an ophthalmologist,
which is not easy or even possible for many patients.
EyeDiagnosis has developed a system that enables primary care
physicians (or other non-specialist practitioners) to use an essentially
automated camera to take images of the retina; those images are then
analyzed by a machine-learning algorithm trained on a gold-standard
dataset of retina images (annotated by expert ophthalmologists).41 The
algorithm returns a diagnosis of more-than-mild diabetic retinopathy,
in which case the patient should seek further care, or not, in which
case the patient should ideally be retested in a year.42 IDx-DR is approved by FDA for this level of autonomous diagnosis and performs
at a level comparable to ophthalmologists, even when operated by
novices.43 In this scenario, the diagnostic expertise is that possessed
by most ophthalmologists (and by their supporting camera technicians). IDx-DR brings that level of diagnostic expertise to primary
care physicians without the relevant experience.44

36. See, e.g., Jill G Klein, Five Pitfalls in Decisions About Diagnosis and Prescribing,
330 BMJ 781, 782 (2005).
37. AI diagnosis is not just about democratizing expertise. AI could also replace very
easy, routine diagnostics (automating drudgery) or point us to disease variants previously
unrecognized (advancing medical knowledge). But to the extent that many maladies are
diagnosable by expert diagnosticians but not by those with less experience or expertise, AI
can help bridge that gap.
38. IDx-DR, IDX, https://www.eyediagnosis.net/idx-dr [https://perma.cc/9GZR-MTUB].
39. AM. ACAD. OF OPHTHALMOLOGY, QUALITY OF CARE SECRETARIAT, INFORMATION
STATEMENT: SCREENING FOR DIABETIC RETINOPATHY 1, 1 (2014), https://www.aao.org/
clinical-statement/screening-diabetic-retinopathy [https://perma.cc/XW88-VZ27].
40. Id. at 2.
41. IDx-DR, supra note 38.
42. Id.
43. See Performance, IDX, https://www.eyediagnosis.net/performance [https://perma.cc/
3Q83-6QLB].
44. In clinical trials for the IDx-DR, the developer specifically sought out technicians
who had not been trained on any retinal imaging system — the opposite of an imaging expert. Id.
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b. Treatment Recommendations
After diagnosis comes treatment. Once providers have determined
what ails the patient, they must select from a menu of possibilities to
determine the best option for improvement.45 Consider a well-trained
and experienced oncologist; knowing that a patient has a certain type
of cancer, she also (hopefully) knows what the best course of treatment is: surgery, radiotherapy, chemotherapy, or some combination — and within each class, which drugs or protocols are likely most
effective, given what she knows about the patient. That expertise, like
diagnostic expertise, is hard-won and hard to apply; becoming a
skilled oncologist takes time, money, and practice. Such expertise is
accordingly hard to come by, especially outside specialized cancer
centers like Memorial Sloan Kettering or MD Anderson.
Medical AI offers possibilities of democratizing expertise here as
well. Indeed, one well-known example of medicine, IBM’s Watson
for Oncology (“Watson Oncology”), addresses exactly this challenge.46 I should note that this example is in some ways a problematic
one. There appears to be some discrepancy between how IBM says
Watson Oncology works and how it actually works in practice, though
details are scarce.47 I will analyze the program as described by IBM,
on the basis that this description is at least aspirational; where others
offer critiques of this account, I’ll note them in footnotes. Whatever
the precise contours of Watson Oncology, it is by far the highestprofile example of using AI to democratize medical expertise existing
today.
Watson Oncology uses machine-learning-based natural language
processing to analyze patient medical records to determine cancer
type and then provides recommendations for treatment.48 The system
is an AI/decision-rule hybrid: AI is involved in the initial stages, but
the treatment recommendation is based not on any particular machinelearning approach, but instead on what oncologists at Memorial Sloan
Kettering would do when faced with a similar patient. 49 IBM aims
45. This picture is naturally somewhat stylized; sometimes, for instance, providers may
need to jump straight from symptoms to treatment without knowing the underlying problem,
as when treating severe dehydration without first determining the cause.
46. IBM Watson Health, IBM, https://www.ibm.com/watson/health/oncology-andgenomics [https://perma.cc/F39K-UF64].
47. Casey Ross & Ike Swetlitz, IBM’s Watson Supercomputer Recommended ‘Unsafe
and Incorrect’ Cancer Treatments, Internal Documents Show, STAT (July 25, 2018),
https://www.statnews.com/2018/07/25/ibm-watson-recommended-unsafe-incorrecttreatments [https://perma.cc/EVP7-AB72].
48. IBM Watson Health, supra note 46. According to STAT, Watson Oncology is actually trained on synthetic patient records (that is, records created by doctors to match typical
patient patterns) rather than actual patient records. Ross & Swetlitz, supra note 47.
49. A. Michael Froomkin et al., When AIs Outperform Doctors: Confronting the Challenges of a Tort-Induced Over-Reliance on Machine Learning, 61 ARIZ. L. REV. 33, 43

No. 1]

Medical AI and Contextual Bias

77

explicitly to use Watson Oncology to democratize medical expertise
(for a price, of course). It licenses Watson Oncology for use at hundreds of hospitals worldwide50 and has evaluated its performance at
hospitals (relatively high-resource hospitals, to be sure) in Thailand,51
India,52 and Mexico.53 Results from initial trials in Mexico conclude
that “Oncologists . . . felt [Watson Oncology] would be particularly
beneficial in clinics that lack subspecialist expertise.”54 Watson Oncology is thus especially targeted at contexts that lack existing oncologist expertise.
Democratization of the expertise needed to recommend treatments, though, does not always translate to democratization of the
expertise needed to actually treat. If medical AI recommends taking
tablet A over tablet B for a particular patient, as long as both tablets
are available, that recommendation may be easy to follow. But if medical AI recommends a complicated surgery, successful implementation depends on the presence of a skilled surgeon. This problem is
explored in more detail below, and is a key challenge for democratizing medical expertise.55
2. Contexts of Application
AI has the potential to democratize medical expertise to many
medical contexts, ranging from other high-resource contexts like ma(2019) (“[Watson Oncology] is really a decision-support tool enhanced with preprogrammed suggestions based on what a committee of doctors at Sloan Kettering said they
would do when presented with various symptoms and scenarios.”).
50. See Watson Health: Get the Facts, IBM, https://www.ibm.com/blogs/watson-health/
watson-health-get-facts [https://perma.cc/KU84-MEBD]; see also Manipal Hospitals
Adopts Watson for Oncology to Help Physicians Identify Options for Individualized, Evidence-Based Cancer Care Across India, IBM (Dec. 2, 2015), https://www-03.ibm.com/
press/us/en/pressrelease/48189.wss [https://perma.cc/5JJP-KWXD].
51. Suthida Suwanvecho et al., Concordance Assessment of a Cognitive Computing System in Thailand, 35 J. CLINICAL ONCOLOGY SUPPLEMENT 6589 (2017),
https://meetinglibrary.asco.org/record/150478/abstract
[https://perma.cc/Y3AU-4W9T]
(abstract presented at the 2017 American Society for Clinical Oncology Annual Meeting).
Notably, some disagreement between Thai oncologist recommendations and Watson Oncology’s recommendations was attributed to “local oncologist preferences.” Id.
52. S.P. Somashekhar et al., Early Experience with IBM Watson for Oncology (WFO)
Cognitive Computing System for Lung and Colorectal Cancer Treatment, 35 J. CLINICAL
ONCOLOGY
SUPPLEMENT
8527
(2017),
http://ascopubs.org/doi/abs/10.1200/
JCO.2017.35.15_suppl.8527 [https://perma.cc/DS38-VFW5] (abstract presented at the 2017
American Society for Clinical Oncology Annual Meeting).
53. Catherine Sarre-Lazcano et al., Cognitive Computing in Oncology: A Qualitative Assessment of IBM Watson for Oncology in Mexico, 35 J. CLINICAL ONCOLOGY e18166
(2017), https://meetinglibrary.asco.org/record/152386/abstract [https://perma.cc/G7B9LW6B] (abstract presented at the 2017 American Society for Clinical Oncology Annual
Meeting).
54. Id. Other appraisals are less complimentary. See Ross & Swetlitz, supra note 47
(quoting a doctor from Jupiter Florida hospital describing the product as “a piece of s—”).
55. See infra Section IV.A.
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jor hospitals, to medium-resource contexts like community hospitals
or community health centers, to low-resource contexts like rural providers in less-developed countries. The higher-resource the destination context, the easier the translation — but the smaller the potential
for transforming medical care.
The most straightforward translation is from the absolute topnotch, very high-resource hospitals to other slightly-less-highresource hospitals — taking the expertise of Memorial Sloan Kettering’s cancer center, for instance, and making it accessible to smaller
hospitals with less specialized or less experienced oncologists. IBM is
already doing this; it’s the easiest path, because those settings already
have the basic resources and infrastructure in place. The information
technology is in place, and oncologists are already on hand who can
take AI recommendations and use them to change — ideally to improve — their own practice (or reject them, as the case may be). 56
This is democratization of expertise on a small scale; very valuable,
but perhaps not transformative. But this is not the only potential context.
Close to the other end of the spectrum, medical AI could be deployed to genuinely low-resource contexts: small rural hospitals,
community health centers or clinics, solo practitioners’ offices or
small doctors’ practices. Where specialists are unavailable — to say
nothing of highly skilled, experienced specialists — medical AI could
make a tremendous difference in the type and level of care that could
be offered. IDx-DR provides exactly this sort of potential: in places
without available ophthalmologists, the AI/camera combination allows providers to check patients with diabetes for diabetic retinopathy, availing themselves of ophthalmologic expertise through the AI
system.57 Deploying AI in these contexts demands resources, but almost certainly far fewer resources than improving care by training and
employing new medical specialists.
AI could truly transform care in the lowest-resource contexts. In
Liberia, as of 2016, there were 298 doctors for a population of 4.5
million, including only fifteen pediatricians and six ophthalmologists.58 In rural India, a single doctor can be responsible for as many

56. See supra note 51 (noting that some Thai oncologists rejected Watson Oncology recommendations based on local preferences); see also Ross & Swetlitz, supra note 47 (noting
that some Watson Oncology recommendations, based on Memorial Sloan Kettering practice, differed from national guidelines); infra Section VI.A (noting difficulties with using
human-in-the-loop safeguards for medical AI generally).
57. See discussion supra Section II.C.1.
58. Al-Varney Rogers, Liberian Doctors Threaten Go-Slow over Salary Arrears, FRONT
PAGE AFR. (Nov. 15, 2016), https://frontpageafricaonline.com/health/liberian-doctorsthreaten-go-slow-over-salary-arrears [https://perma.cc/MGA3-LLCG] (citing a July 2016
report by the Liberia Medical and Dental Council).
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as 30,000 residents in the rural health system.59 In such low-resource
environments, medical AI could provide front-line access for simple
diagnostics and treatment recommendations, triaging patients who
need to seek further help, as well as the more complex tasks that AI
can facilitate in higher-resource contexts. In India, where the doctor
shortage extends to ophthalmologists, the Google AI team is already
deploying its own AI system to diagnose diabetic retinopathy for patients who cannot access ophthalmologists for recommended yearly
screenings. 60 Further work has suggested that smartphones may be
suitable for such machine-learning diagnoses, which could lower the
barriers to AI-mediated care even further.61 Overall, while AI has the
potential to incrementally improve care in relatively high-resource
settings, it could revolutionize care in very low-resource contexts.
***
Medical AI can make a difference in many areas of medicine, but
one of the most exciting is democratizing medical expertise, especially by bringing diagnostic and treatment recommendation expertise to
lower-resource settings where they are otherwise unavailable. The
next Part explores the first part of that process: developing algorithms
that incorporate medical expertise.

III. WHERE MEDICAL AI IS DEVELOPED — AND WHY
Black-box medical algorithms are predominantly developed in
partnership with high-resource medical settings. These are often academic medical systems, but I also include high-resource standalone
hospitals. I’ll refer to the group collectively as “High-Resource Hospitals.” In a typical arrangement, the AI system developer partners with
the High-Resource Hospital with an agreement to use the HighResource Hospital’s data to train and develop a new medical algorithm. In the examples above, IBM’s Watson Oncology partners with
59. Devarsetty Praveen et al., SMARTHealth India: Development and Field Evaluation of
a Mobile Clinical Decision Support System for Cardiovascular Diseases in Rural India, 2
JMIR MHEALTH & UHEALTH, Oct.–Dec. 2014, at e54, https://mhealth.jmir.org/2014/4/e54/
pdf [https://perma.cc/73M5-2RV4].
60. Kamala Thiagarajan, The AI Program That Can Tell Whether You May Go Blind,
GUARDIAN: THE UPSIDE (Feb. 8, 2019, 1:00 AM), https://www.theguardian.com/world/
2019/feb/08/the-ai-program-that-can-tell-whether-you-are-going-blind-algorithm-eyedisease-india-diabetes [https://perma.cc/Y6AY-CW2X]; see also Varun Gulshan et al.,
Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs, 316 J. AM. MED. ASS’N 2402, 2402 (2016) (describing an AI diagnostic system).
61. Ramachandran Rajalakshmi et al., Automated Diabetic Retinopathy Detection in
Smartphone-Based Fundus Photography Using Artificial Intelligence, 32 EYE 1138, 1138
(2018).
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Memorial Sloan Kettering62 and EyeDiagnosis partners with the University of Iowa Health System and the University of Arizona.63 At the
academic/pre-development level, similar patterns manifest: over 500
medical AI studies have been based on the MIMIC dataset, the mostused publicly available health dataset for AI — which includes data
only from patients seen at Beth Israel Deaconess Medical Center, a
high-resource Harvard-affiliated hospital in Boston.64
Developer focus on High-Resource Hospitals does not reflect the
delivery of medical care, either nationally or worldwide. Academic
medical centers, for instance, make up only a small fraction of all
hospitals, and deliver a small (though larger) fraction of care.65 Many
more medical encounters take place in practitioner offices, community
health centers, or community hospitals than in High-Resource Hospitals of various flavors.
Algorithm developers partner with High-Resource Hospitals for a
varying combination of technical, legal, and business reasons.66 First
and most importantly, High-Resource Hospitals are more likely to
have large, high-quality data sets. Second, training algorithms on data
from High-Resource Hospitals may facilitate convincing potential
clients or insurers that the algorithm is high-quality and worth paying
for. Third, training algorithms on High-Resource Hospital data decreases the risk of adverse outcomes from three legal processes: receiving regulatory approval, avoiding tort liability for potential
problems once the algorithm is in use, and winning reimbursement
from payers.

62. Memorial Sloan Kettering Trains IBM Watson to Help Doctors Make Better Cancer
Treatment Choices, MEMORIAL SLOAN KETTERING CANCER CTR. (Apr. 11, 2014),
https://www.mskcc.org/blog/msk-trains-ibm-watson-help-doctors-make-better-treatmentchoices [https://perma.cc/HB8U-36VT].
63. Pipeline, IDX, https://www.eyediagnosis.net/pipeline [https://perma.cc/L5W4-S2UZ].
64. Rebecca Robbins, How Patient Records from One Boston Hospital Fueled an Explosion in AI Research in Medicine, STAT (July 12, 2019), https://www.statnews.com/2019/
07/12/boston-hospital-records-fuel-artificial-intelligence-research [https://perma.cc/YGF6AKWZ].
65. See, e.g., Joanna Bisgaier et al., Academic Medical Centers and Equity in Specialty
Care Access for Children, 166 ARCHIVES PEDIATRICS & ADOLESCENT MED. 304, 304
(2012) (observing that academic medical centers were “only 6% of the nation’s hospitals
[yet] provide 28% of all discharges of Medicaid enrollees”); Academic Medical Centers:
Shaping the Future of Healthcare, UCI HEALTH (June 23, 2016), http://www.ucihealth.org/
news/2016/06/academic-medical-centers-future-of-healthcare
[https://perma.cc/F89NBY65] (noting that “[a]cademic medical centers make up 2 to 2.5 percent of all hospitals in
the country”).
66. I do not claim that all of these reasons apply in each case, and they may be of varying
strength; one anonymous industry insider, for instance, described data availability as a
“need to have” and potential easing of FDA review as “nice to have.”
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A. That’s Where the Data Are
The first reason for developer focus on High-Resource Hospitals
is fundamental: High-Resource Hospitals have more data. Indeed,
they may be the only places that actually have high-volume, highquality data. To take one simple example: health data are hard to use
or access unless they are in electronic format. In health care settings,
that typically means that the data are recorded in an electronic health
record.67 By now, electronic health records are almost universal; by
2017, essentially all hospitals had adopted electronic health records
systems, as had about 90% of office-based practices.68 However, if a
developer wants longitudinal data, or the ability to track results over
time, adoption one or two years ago is insufficient — and in 2008,
only about 10% of hospitals had EHR systems in place.69 Which hospitals were those? High-Resource Hospitals.70
The mere presence of electronic health records is not enough. For
a health-care provider to collect data that can be used to develop medical AI, the provider needs the right infrastructure. 71 This includes
developing (1) systems so that providers input the right data, in the
right format; (2) databases to ensure that data are collected, categorized, and made available for future use; and (3) quality checks to ensure that the data collected are correct. 72 This infrastructure can be
67. Other health data that can be used for training medical AI include pharmacy records
or insurance claims data — or non-medical data such as internet search histories or personal
health trackers. See generally SHARONA HOFFMAN, ELECTRONIC HEALTH RECORDS AND
MEDICAL BIG DATA: LAW AND POLICY (2016). These, too, need to be in electronic format.
However, electronic health records are the most direct source of data about health-care
encounters in particular. Id. at 9.
68. Vindell Washington et al., The HITECH Era and the Path Forward, 377 NEW ENG. J.
MED. 904, 904–05 (2017). Electronic health record adoption received a substantial push in
the HITECH Act, which largely mandated their adoption. See What is the HITECH Act?,
HIPAA J., https://www.hipaajournal.com/what-is-the-hitech-act [https://perma.cc/8W635BJ2].
69. Washington et al., supra note 68, at 905 (showing data for nonfederal acute care hospitals). Older, paper-based records may be digitized by scanning, but such data migration
creates a complicated hybrid system. See, e.g., Diane Dolezel & Jackie Moczygemba, Implementing EHRs: An Exploratory Study to Examine Current Practices in Migrating Physician Practice, 12 PERSP. HEALTH INFO. MGMT., Winter 2015, at 1e, 1e,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700870/pdf/phim0012-0001e.pdf
[https://perma.cc/39DX-RP7D]. Eventually, this problem will lessen as even new EHR
systems acquire longitudinal data over time — but that will take substantial time, by definition, and if developers are to take advantage of that eventual broadening, policymakers must
ensure that the current system is not locked in as the default, legal and otherwise.
70. See, e.g., John D. Halamka et al., Early Experiences with Personal Health Records,
15 J. AM. MED. INFORMATICS ASS’N 1, 1 (2008) (describing early EHR systems at the Palo
Alto Medical Foundation, Beth Israel Deaconess Medical Center, and Boston Children’s
Hospital).
71. Price, Big Data, supra note 30, at 1413.
72. Id. at 1411–15; see also Sharona Hoffman & Andy Podgurski, The Use and Misuse of
Biomedical Data: Is Bigger Really Better?, 39 AM. J.L. & MED. 497, 515–20 (2013) (describing pitfalls and precautions for biomedical database development).
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complex, challenging, and expensive.73 It demands information technology resources, data scientists or data managers (themselves in
short supply), and attention from management.74 These requirements
are a priori harder to meet for low-resource health-care providers than
for High-Resource Hospitals — they have fewer resources, by definition — skewing the distribution of health-record data to the latter context.
Law also creates hurdles to the collection and use of big health
data for research purposes, especially through the Health Insurance
Portability and Accountability Act’s75 Privacy Rule (the HIPAA Privacy Rule) 76 and requirements for informed consent. 77 Under the
HIPAA Privacy Rule, “covered entities” — including essentially all
health-care providers and hospitals78 — are prohibited from using or
disclosing individually identifiable health information without authorization, except for a list of specifically identified purposes.79 Research
is not one of those specifically identified purposes.80 Providers wishing to use patient data for research purposes must therefore either obtain individual authorization 81 (a closely prescribed and potentially
sample-biasing process)82 or remove identifying information from the
sample (which makes linking different data together difficult).83
The requirement to obtain informed consent and research approval for use of patient data similarly imposes costs on that use.84 In73. See Hoffman & Podgurski, supra note 72; Price, Big Data, supra note 30, at 1411–
15.
74. HOFFMAN, supra note 67, at 152–68; see also Hoffman & Podgurski, supra note 72,
at 527–32; Price, Big Data, supra note 30, at 1414–15.
75. Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191,
110 Stat. 1936 (codified as amended in scattered sections of 26, 29, and 42 U.S.C.).
76. Standards for Privacy of Individually Identifiable Health Information, 45 C.F.R. §§
160, 164 (2018). State privacy rules also come into play and further complicate the situation. See Barbara J. Evans, The Ethics of Postmarketing Observational Studies of Drug
Safety Under 505(o)(3) of the Food, Drug, and Cosmetic Act, 38 AM. J.L. & MED. 577, 594
(2012).
77. See W. Nicholson Price II, Drug Approval in a Learning Health System, 102 MINN.
L. REV. 2413, 2446–48 (2018) [hereinafter Price, Drug Approval].
78. 45 C.F.R. § 160.103 (2018).
79. Id. § 164.502.
80. See Rebecca S. Eisenberg & W. Nicholson Price II, Promoting Healthcare Innovation on the Demand Side, 4 J.L. & BIOSCIENCES 3, 35–36 (2017) (describing the lack of a
research exemption, and noting that the “operations” and “quality improvement” exemptions do not cover research).
81. See Kayte Spector-Bagdady & Andrew G. Shuman, Reg-ent Within the Learning
Health System, 158 OTOLARYNGOLOGY — HEAD & NECK SURGERY 405, 405 (2018).
82. See, e.g., Sharona Hoffman & Andy Podgurski, Balancing Privacy, Autonomy, and
Scientific Needs in Electronic Health Records Research, 65 SMU L. REV. 85, 114–19
(2012) (describing this bias).
83. See Eisenberg & Price, supra note 80, at 36–37.
84. See, e.g., Hoffman & Podgurski, supra note 82, at 123 (describing empirical evidence
on informed consent costs); Mark J. Pletcher et al., Informed Consent in Randomized Quality Improvement Trials: A Critical Barrier for Learning Health Systems, 174 JAMA
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formed consent requirements are part of a suite of oversight and ethical requirements,85 typically enforced by institutional review boards
that review research.86 Obtaining informed consent for research use of
patient data can be an arduous and costly process.87
These legal hurdles tend to concentrate the collection and use of
patient health data for research purposes in High-Resource Hospitals.
The hurdles may be justified — though that claim has been questioned88 — and certainly were put in place to serve laudable aims.89
Nevertheless, the costs imposed by these legal hurdles weigh especially heavily in low-resource contexts, like small hospitals, community
health centers, or solo practitioners in rural areas, which have fewer
resources to start with. Even de-identifying patient data to comply
with the HIPAA Privacy Rule and informed consent requirements
may impose its own costs.90 Those low-resource settings are unlikely
to have the resources to spend on addressing legal compliance issues,
just as they are unlikely to have spare resources to meet the technological requirements for a useful data infrastructure that can support
future research.91 These resource constraints help drive the concentration of medical big data — and the concomitant ability to develop
black-box medical algorithms — in high-resource contexts.
B. Reputational Effects
Reputational effects also push algorithm developers to partner
with High-Resource Hospitals. Developers of black-box medical algorithms must persuade potential clients that these algorithms will provide excellent results, whether diagnoses or treatment

INTERNAL MED. 668, 668 (2014) (describing how informed consent requirements make
large-scale clinical trials and data collection more challenging).
85. See, e.g., Ruth R. Faden et al., Informed Consent, Comparative Effectiveness, and
Learning Health Care, 370 NEW ENG. J. MED. 766, 768 (2014).
86. See Price, Drug Approval, supra note 77, at 2446 n.208.
87. See id. at 2457; Charlotte A. Tschider, The Consent Myth: Improving Choice for Patients of the Future, 96 WASH. U. L. REV. 1505, 1507 (2019) (finding HIPAA’s informed
consent process largely incompatible with health AI).
88. See, e.g., Price, Drug Approval, supra note 77, at 2449–52. See generally CARL E.
SCHNEIDER, THE CENSOR’S HAND (2015) (critiquing research oversight by institutional
review boards, including the procedural requirements of informed consent).
89. See, e.g., Nancy E. Kass et al., The Research-Treatment Distinction: A Problematic
Approach for Determining Which Activities Should Have Ethical Oversight, 43 HASTINGS
CTR. REP., S4, S5 (Jan.–Feb. 2013).
90. See, e.g., Elizabeth Ford et al., Extracting Information from the Text of Electronic
Medical Records to Improve Case Detection: A Systematic Review, J. AM. MED.
INFORMATICS ASS’N 1007, 1013 (2016).
91. Interview with Researcher, Univ. of Mich. (Feb. 2018) (describing the process of developing a learning health system at a low-resource Michigan health system); Interview
with Medical AI Researcher, Vanderbilt Univ. (July 2018).
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recommendations.92 Making that pitch is likely easier when the developer can state that the algorithm is trained on data from presumably
expert doctors at High-Resource Hospitals, rather than a more run-ofthe-mill medical practice.93 IBM, for instance, notes that “Watson for
Oncology can provide clinicians with evidence-based treatment options based on expert training by Memorial Sloan Kettering (MSK)
physicians.”94
C. Legal Influences
Finally, three legal regimes also suggest the utility of training algorithms with data from practitioners at the top of their profession:
FDA approval, tort liability, and insurer reimbursement. In no case
does the legal regime require high-resource context training, but in
each case risk-averse developers may find that such training decreases
the possibility of unexpected problems.
1. FDA Approval
Many forms of medical AI will require FDA approval to be marketed. The FDA regulates “medical devices” under the Federal Food,
Drug, and Cosmetics Act and defines “device” quite broadly so that
many forms of medical AI will qualify.95 The FDA has released guidance on regulating Software as a Medical Device (“SaMD”) generally96 and has also released guidance on regulation of clinical decision
support software under the 21st Century Cures Act (“Cures Act”).97
Both suggest that FDA will regulate medical AI.98 And indeed, a few
92. See Price, Black-Box Medicine, supra note 2, at 465–66. Empirical studies on the
challenge of provider adoption present an interesting avenue for future work. To my
knowledge, none yet exist.
93. Interview with Lawyer for a Major Medical AI Developer (May 2018).
94. IBM Watson Health, supra note 46; see supra Section II.C.1.b.
95. See 21 U.S.C. § 321(h) (2012).
96. See FDA, SOFTWARE AS A MEDICAL DEVICE (SAMD): CLINICAL EVALUATION —
GUIDANCE FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF (2017),
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/softwaremedical-device-samd-clinical-evaluation-guidance-industry-and-food-and-drugadministration [https://perma.cc/VCH3-CJUG].
97 . See FDA, CLINICAL DECISION SUPPORT SOFTWARE: DRAFT GUIDANCE FOR
INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF (2019), https://www.fda.gov/
regulatory-information/search-fda-guidance-documents/clinical-decision-support-software
[https://perma.cc/GP6D-CXEY]; 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat.
1033, 1130–33 (2016) (amending 21 U.S.C. § 360j (2012)).
98. See W. Nicholson Price II, Regulating Black-Box Medicine, 116 MICH. L. REV. 421,
439–42 (2017). Under the 21st Century Cures Act, many forms of clinical decision support
software are excluded from the definition of medical devices. 21st Century Cures Act, Pub.
L. No 114-255, 130 Stat. at 1130–33 (2016). That is, software that merely informs doctors
of treatment options or that makes recommendations may not be regulated as a medical
device — but only if the software provides an explanation of its recommendations and al-
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devices using medical AI have already been allowed on the market by
FDA, including one product that uses machine learning to estimate
cardiac volume;99 one product that identifies radiological images of
breast abnormalities for further review;100 and one product, the IDxDR mentioned above, that analyzes retinal images to autonomously
diagnose diabetic retinopathy.101 Many more medical AI devices are
likely to come through FDA’s approval or clearance pathways.102
Training medical AI with high-quality data from high-resource
contexts may ease the path to FDA approval. The FDA does not yet
have any explicit standards or rules about the quality or source of data
used in training medical AI.103 In a sense, the agency is learning as it
goes along in this area of very new technology. 104 Nevertheless, all

lows the provider “to independently review the basis for such recommendations . . . so that
it is not the intent that such [providers] rely primarily on any of such recommendations to
make a clinical diagnosis or treatment decision regarding an individual patient.” 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. at 1131 (2016). Medical AI — at least the type
of medical diagnosis and treatment AI discussed here — will rarely meet this description
because it will typically be unable to provide reasoning sufficient for independent review.
See Price, supra, at 440. This will not be the case for all medical AI; some systems at least
make claims to explain the reasoning behind their decisions, though this is a contested area
and there may be tradeoffs between algorithmic performance and explainability requirements. Other types of AI are not medical devices because they do not inform or direct the
care of individual patients; AI used in billing, or to provide medical literature references to
doctors, would be excluded. See, e.g., 21st Century Cures Act, Pub. L. No. 114-255, 130
Stat. at 1131 (2016). Nevertheless, as described below, even when FDA approval is not
required, such as for devices with sufficient explainability to sit within § 3060’s exemption,
FDA approval brings other benefits. See infra Section III.C.3.
99. Letter from FDA to Arterys, Inc. (Jan. 5, 2017), https://www.accessdata.fda.gov/
cdrh_docs/pdf16/K163253.pdf [https://perma.cc/H6M4-6QQH] (determining that the Arterys Cardio DL system is substantially equivalent to legally marketed predicate devices).
100 . Letter
from
FDA
to
Quantitative
Insights,
Inc.
(July
19,
2017),
https://www.accessdata.fda.gov/cdrh_docs/pdf17/DEN170022.pdf
[https://perma.cc/UX5U-T2X5] (classifying QuantX as a Class II medical device under the
de novo pathway).
101. Press Release, FDA, FDA Permits Marketing of Artificial Intelligence-Based Device to Detect Certain Diabetes-Related Eye Problems (Apr. 11, 2018),
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604357.htm
[https://perma.cc/5K8X-JMBU].
102. The extent to which FDA will evaluate AI medical devices as components of a larger system or holistically is also unclear. See Tschider, supra note 20, at 207 (describing
limitations of classifying health-care AI systems as components when they may be used for
differing diagnostic purposes).
103. Interview with Senior FDA Official (June 2018).
104. Interviews with Regulatory Affairs Personnel at Medical AI Developers (May and
June 2018); see FDA, Challenge Questions, https://www.fda.gov/downloads/
MedicalDevices/DigitalHealth/DigitalHealthPreCertProgram/UCM605686.pdf
[https://perma.cc/SA26-5BWV]; FDA, Digital Health Software Precertification (Pre-Cert)
Program,
https://www.fda.gov/medicaldevices/digitalhealth/digitalhealthprecertprogram/
default.htm [https://perma.cc/AB4S-5VST].
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things being equal, training algorithms on the highest quality data
available removes at least one cause for risk and uncertainty.105
2. Tort Liability
The tort regime also creates incentives for medical AI development.106 The tort landscape for medical AI is largely theoretical, as the
technology is just entering practice. Even the limited scholarly work
on the topic has focused more on medical malpractice liability of providers using medical AI, rather than on liability for the developers of
the AI products.107 If a patient is injured through the failure of medical
AI, however, liability could be found for developers on theories of
negligence or strict liability, alleging design or manufacturing defect. 108 Successful tort claims against a medical AI developer face
numerous challenges, including identifying the injury, demonstrating
causation within the context of opaque recommendations, overcoming
the reluctance of courts to find liability for software generally,109 and
avoiding the doctrine of the learned intermediary.110 But there is still a
risk of liability.
High-quality data from high-resource settings could serve as potential insulation from possible tort liability. It is not clear whether
design defect or manufacturing defect would more accurately encapsulate a failure to train an algorithm correctly. But training algorithms
on data from excellent doctors in high-resource settings creates an
easier case that the developer exercised due care in the development
process. To the extent that developing algorithms based on high105. All things may not be equal. For instance, if a lower-resource setting also provides
lower-quality care (not a certainty), then an AI system could more easily show a greater
effect in the lower-resource setting.
106. Tort law shapes other aspects of the development of black-box medicine. See, e.g.,
W. Nicholson Price II, Medical Malpractice and Black-Box Medicine, in BIG DATA,
HEALTH LAW, AND BIOETHICS 295, 295–96 (I. Glenn Cohen et al. eds., 2018) [hereinafter
Price, Medical Malpractice]; Froomkin et al., supra note 49, at 35. Among other aspects, to
the extent that tort law relies on demonstrating causation, and to the extent that demonstrating causation is hampered by essentially opaque machine-learning algorithms, we might
expect that tort law pushes medical AI away from explainability and reliance on explicit
factors, and toward models that are harder to interrogate — and therefore harder landscapes
to pinpoint causation.
107. See, e.g., Froomkin et al., supra note 49, at 55; Price, Medical Malpractice, supra
note 106, at 295; Nicolas P. Terry & Lindsay F. Wiley, Liability for Mobile Health and
Wearable Technologies, 25 ANNALS HEALTH L. 62, 81 (2016).
108. Cf. Daniel A. Crane, et al., A Survey of Legal Issues Arising from the Development
of Autonomous and Connected Vehicles, 23 MICH. TELECOMM. & TECH. L. REV. 191, 261
(2017) (discussing potential products liability claims against software providers in the event
of an autonomous vehicle crash).
109. Cf. Frances E. Zollers et al., No More Soft Landings for Software: Liability for Defects in an Industry that Has Come of Age, 21 SANTA CLARA COMPUTER & HIGH TECH. L.J.
745, 766 (2004).
110. See Timothy S. Hall, Reimagining the Learned Intermediary Rule for the New
Pharmaceutical Marketplace, 35 SETON HALL L. REV. 193, 195 (2004).
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resource data becomes standard practice, failure to do so — if injuries
result — could potentially be viewed as a failure to exercise due care
in development.111
Although tort law seems unlikely to be a principal source of incentives to develop algorithms on high-resource data, it likely reinforces existing pressures in that direction.
3. Insurer Reimbursement
Finally, convincing insurers that these new technologies should
be reimbursed could easily follow a similar pattern.112 Training algorithms on the data from highly skilled doctors is at least a proxy signal
of quality. All things being equal, it suggests that the algorithms are
likely to be higher quality, and therefore worthier of reimbursement.
While the source of the training data is unlikely completely to replace
other quality metrics (e.g., patient outcomes, decreased costs), linking
an algorithm to the reputation of its training data may supplement
those metrics on the path to reimbursement by payers.113
***
These issues are not totally distinct. The link between FDA approval and reimbursement by the Centers for Medicare and Medicaid
Services (“CMS”), the largest payer in the United States, is substantial
for drugs, though less so for medical devices in general.114 However,
the link is prominent in the development of new diagnostic tests, including those reliant on big data. 115 Foundation Medicine pursued
FDA approval of its Foundation One biomarker test simultaneously
with CMS review for payment in a prominent example of joint FDA
approval/CMS coverage determination. 116 CMS suggested that the
111. See Froomkin et al., supra note 49, at 36–37, 49 (arguing that as medical AI improves, it will become standard of care to use it and a failure to do so might result in liability).
112. See, e.g., Rachel E. Sachs, Prizing Insurance: Prescription Drug Insurance as Innovation Incentive, 30 HARV. J.L. & TECH. 153, 178–79 (2016) (describing insurance reimbursement process); cf. Rebecca S. Eisenberg & Harold Varmus, Insurance for Broad
Genomic Tests in Oncology, 358 SCI. 1133, 1133 (2017) (describing the practice of insurers
declining to cover new next-generation sequencing techniques because of lack of clinical
evidence).
113. See Price, Black-Box Medicine, supra note 2, at 462–64 (discussing reimbursement
challenges for black-box medicine).
114. See Rachel E. Sachs, Delinking Reimbursement, 102 MINN. L. REV. 2307, 2309,
2311, 2342 (2018).
115. See Rachel E. Sachs, Innovation Law and Policy: Preserving the Future of Personalized Medicine, 49 U.C. DAVIS L. REV. 1881, 1885 (2016).
116. See Eisenberg & Varmus, supra note 112, at 1134; Press Release, FDA, FDA Announces Approval, CMS Proposes Coverage of First Breakthrough-Designated Test to
Detect Extensive Number of Cancer Biomarkers (Nov. 30, 2017), https://www.fda.gov/
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level of reimbursement available for such next-generation diagnostics
would be linked to the type of FDA review sought.117 Devices taken
through FDA’s more stringent Class III approval pathway would receive full reimbursement, while devices that were only “cleared”
through FDA’s less-stringent 510(k) clearance pathway would receive
lower reimbursement rates.118 This stringent difference did not make
it into final policy.119
FDA approval is also linked to tort liability. State tort lawsuits alleging negligent design of medical devices are preempted if the device
was approved by FDA through the premarket approval process (but
not if the device was cleared under the 510(k) pathway).120 Thus, to
the extent that the FDA approval pathway is smoothed by the demonstration of high-quality data reliance, that also has indirect impacts on
the ease of obtaining reimbursement for the product and on reducing
tort liability.
D. Caveats
The reliance on medical data from High-Resource Hospitals is
both over-determined and under-determined. In many situations, firms
will rely on High-Resource Hospital data for multiple reasons, any
combination of which may be independently sufficient. By contrast, in
two notable exceptions, algorithms may be trained on data from different sources.
First, some types of medical data are so highly standardized that
the particular setting from which they arise does not matter very
much. For instance, because ophthalmological examinations are highly standardized, the field has developed gold-standards for images and

news-events/press-announcements/fda-announces-approval-cms-proposes-coverage-firstbreakthrough-designated-test-detect-extensive [https://perma.cc/ZBL2-A7SM].
117. See CTRS. MEDICARE & MEDICAID SERVS., PROPOSED DECISION MEMO FOR NEXT
GENERATION SEQUENCING (NGS) FOR MEDICARE BENEFICIARIES WITH ADVANCED
CANCER (CAG-00450N) (Nov. 30, 2017), https://www.cms.gov/medicare-coveragedatabase/details/nca-proposed-decision-memo.aspx?NCAId=290 [https://perma.cc/LP8RPVFS]; Rebecca S. Eisenberg, Opting into Device Regulation in the Face of Uncertain
Patentability, MARQ. INTELL. PROP. L. REV. (forthcoming) (draft on file with author) [hereinafter Eisenberg, Device Regulation].
118. See Eisenberg, Device Regulation, supra note 117, at 20–21; Price, Regulating
Black-Box Medicine, supra note 98, at 438 (describing the approval and clearance pathways).
119. See CTRS. MEDICARE & MEDICAID SERVS., DECISION MEMO FOR NEXT
GENERATION SEQUENCING (NGS) FOR MEDICARE BENEFICIARIES WITH ADVANCED
CANCER (CAG-00450N) (Mar. 16, 2018), https://www.cms.gov/medicare-coveragedatabase/details/nca-decision-memo.aspx?NCAId=290 [https://perma.cc/WB86-AXWW].
120. See Riegel v. Medtronic, Inc., 552 U.S. 312, 323, 326–27 (2008) (finding preemption for devices that underwent premarket approval); Medtronic, Inc. v. Lohr, 518 U.S. 470,
496–98 (1996) (finding no preemption for devices cleared through 510(k)).
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diagnoses for use in training ophthalmologists, and these data can
similarly be used to train medical AI.121
Second, the picture changes drastically in an international context. The particular patterns of health data acquisition, storage, and
use — especially legal, but also technical — are artifacts of the peculiar American health system. For instance, when the federal government mandated that hospitals and other providers adopt EHRs, it left
the choice of system to the market.122 As a result, different providers
and hospitals use different EHR systems, which makes it hard to assemble data from different medical environments. 123 In China and
some other international contexts, on the other hand, the central government mandates specific EHRs and their adoption, and data collection is thus more widespread and uniform across different medical
contexts, though those contexts may bring other challenges.124 Algorithms trained on foreign data, then, may be less likely to rely on data
from High-Resource Hospitals.125
On the other hand, reliance on U.S. data from High-Resource
Hospitals may be over-determined in some cases. The concentration
of those data at High-Resource Hospitals may be a sufficient condition to drive company reliance on High-Resource Hospital data, because without those data, there is nothing on which to train the
algorithms. However, the other factors mentioned — reputation and
avoidance of legal risks — might themselves be independently sufficient were the data to become available from more contexts.126 This
matters because if use of data from High-Resource Hospitals is indeed
over-determined for a subset of algorithm developers, then fixing
merely one problem — availability of data or a broader path to FDA
121 . See
WISCONSIN
FUNDUS
PHOTOGRAPH
READING
CENTER,
https://www.ophth.wisc.edu/research/fprc [https://perma.cc/S8W3-RF88].
122. See HOFFMAN, supra note 67, at 1–2.
123. See Price, Risk and Resilience, supra note 32, at 70.
124. See, e.g., Luxia Zhang et al., Big Data and Medical Research in China, 360 BMJ,
Feb. 5, 2018, at 1–2. Of course, there may be other concerns with centrally-mandated EHR;
for instance, although the United Kingdom developed a plan to centralize health data for
biomedical research, that process was halted amid intense controversy. See Siobhan Fenton,
Controversial Mega-database of Medical Records Scrapped Over Privacy Concerns,
INDEPENDENT (July 6, 2016), https://www.independent.co.uk/life-style/health-and-families/
health-news/nhs-database-medical-records-care-data-scrapped-privacy-concerns-chilcotreport-a7123126.html [https://perma.cc/7FAR-33V9].
125. See, e.g., Kasumi Widner & Sunny Virmani, New Milestones in Helping Prevent
Eye Disease with Verily, GOOGLE (Feb. 25, 2019), https://www.blog.google/technology/
health/new-milestones-helping-prevent-eye-disease-verily [https://perma.cc/5BCK-7XU9]
(describing Google working with data from a chain of Indian eye hospitals). But see Corinne
Abrams, Google’s Effort to Prevent Blindness Shows AI Challenges; Company’s AI Can
Detect a Condition That Causes Blindness in Diabetes Patients, But in Rural India It
Doesn’t Always Work, WALL ST. J. (Jan. 26, 2019), https://www.wsj.com/articles/googleseffort-to-prevent-blindness-hits-roadblock-11548504004 [https://perma.cc/V3GU-WZDJ]
(describing challenges using Google’s algorithms in field clinics).
126. See supra Sections III.B–C.
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approval, for instance — will not actually result in medical AI being
trained on data from different contexts. Instead, solving just part of
the problem may result in developers continuing to train principally
on data from High-Resource Hospitals.
But what is the impact of training medical AI on data from HighResource Hospitals? The reasons listed above all seem reasonable
justifications for training algorithms on those data. What’s the problem? The next Part explores the challenges that arise in translating
algorithms trained on data from High-Resource Hospitals into lesselite health-care settings.

IV. TRANSLATIONAL CHALLENGES
The promise of black-box medicine — at least, the promise that is
the focus of this work — is that it can help democratize medical expertise, raising the level of run-of-the-mill practitioners and improving
medical care. Achieving those goals requires that algorithms actually
be deployed in those run-of-the-mill settings. How will algorithms
trained on data from High-Resource Hospitals fare outside those settings? This Part argues that problems are likely to arise in translation
in two principal areas: quality of care and cost of care.
One preliminary note: other technical challenges arise in the process of translation itself, which are not the focus of this Part. For example, it can be difficult to ensure that algorithms trained on data
from one electronic health record system can accurately analyze data
within the context of another electronic health record system.127 One
study found that an algorithm developed in Washington state to identify lung cancer patients who would likely respond to targeted therapy
performed well in Washington, but quite poorly in Kentucky, based in
part on different language used in electronic health records.128 Such
technical issues may be particularly likely when the deployment context is relatively under-resourced; community health centers may be
ill-equipped to deal with EHR incompatibility issues, for instance.
Nevertheless, even if these more straightforward technical hurdles are
overcome, less visible challenges of decreased patient care quality and
increased cost may remain.129

127. See Price, Risk and Resilience, supra note 32, at 71.
128. See Bernardo Haddock Lobo Goulart et al., Validity of Natural Language Processing for Ascertainment of EGFR and ALK Test Results in SEER Cases of Stage IV NonSmall-Cell Lung Cancer, JCO CLINICAL CANCER INFORMATICS 1, 7 (2019).
129. In fact, overcoming technical challenges may give a false sense of security, thus obscuring the other problems that arise in translation.
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A. Treatment Quality
The most significant problem with applying algorithms developed
in High-Resource Hospitals in lower-resource settings is that those
algorithms are likely to make diagnoses and treatment recommendations that are systematically suboptimal in those lower-resource settings. These can arise in at least two different ways: differences in
diagnoses and treatment recommendations based on systematically
different patient populations, and differences in recommended treatments based on treatment rankings whose order shifts with available
medical resources. This distinction is a bit abstract, so the next sections will illustrate with examples from current care and then describe
how these examples could become embedded in relatively opaque
black-box algorithms and negatively impact the quality of care.
1. Patient Population Differences
Algorithmic translation can cause problems in care when there are
systematic differences between the patient populations used to train
the algorithm and those where the algorithm is later used. If the patients in the training data — the High-Resource Hospital — differ
systematically from the patients in low-resource settings where the
algorithm is deployed as part of an AI system, the system won’t do a
good job dealing with those patients.
Patient population differences, including ancestral origin/genetic
variation, socioeconomic status,130 or general health status,131 can influence recommendations for treatment in many ways. These differences can influence both proper diagnosis and proper treatment.
Consider two examples, one on the prediction side and one on the
treatment side.
A prominent example on the diagnosis/prophylactic front comes
from hypertrophic cardiomyopathy. 132 In this condition, the wall of
the heart thickens abnormally, potentially leading to abnormal
rhythms and even sudden death; it is particularly dangerous for young
athletes who can be asymptomatic and then die during strenuous exer130. See, e.g., Dhruv Khullar, A.I. Could Worsen Health Disparities, N.Y. TIMES
(Jan. 31 2019), https://www.nytimes.com/2019/01/31/opinion/ai-bias-healthcare.html
[https://perma.cc/6QXJ-SQZS] (noting AI may entrench current inequities in health: “If, for
example, poorer patients do worse after organ transplantation or after receiving chemotherapy for end-stage cancer, machine-learning algorithms may conclude such patients are less
likely to benefit from further treatment — and recommend against it.”).
131. For instance, of all patients with a particular disease, those with the most severe
symptoms might disproportionately choose to go to High-Resource Hospitals, which would
skew the data from which an algorithm could learn.
132. See Arjun K. Manrai et al., Genetic Misdiagnoses and the Potential for Health Disparities, 375 NEW ENG. J. MED. 655, 655 (2016).
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tion.133 Genetic tests are used to identify the disorder — but a 2016
study found that black Americans were underrepresented in the initial
data, and as a result many black patients were told they were at risk
based on a mutation that does not in fact predict a higher risk for
them.134 Medical AI could easily use this type of genetic information,
especially once genetic sequencing becomes more common, to drive
preliminary diagnoses and recommendations for further screening —
and unless that medical AI was trained on more representative data, it
would provide poor results for underrepresented groups.135
On the treatment side, consider clopidogrel, marketed in the United States as Plavix for preventing heart attacks and stroke. 136 The
gene CYP2C19 is related to the efficacy of clopidogrel. One particular
CYP2C19 allele reduces how well clopidogrel works — but only appears in those of European ancestry 10–20% of the time, as opposed
to those of Pacific Islander descent (40–77%) or East Asian descent
(23–45%).137 Unfortunately, 95% of participants in the initial clinical
studies were of European descent — leading to the conclusion that the
drug is much more broadly effective than it actually is.138 The state of
Hawaii sued Bristol-Myers Squibb and Sanofi-Aventis, the makers of
Plavix, for false, unfair, and deceptive marketing based on the failure
to disclose that treatment efficacy differed based on patient populations.139
Differences between patients are well-recognized. Those differences drive the development of precision medicine: the idea that medical treatment should take into account the characteristics of each
individual patient.140 For drugs, that means getting the right drug to
the right patient, at the right time.141 For medicine to take those differences into account, though, especially AI, medical technologies need
to be developed in environments that actually show representative
variation. If, as posited here, certain types of variation are not reflected in development environments, those potential benefits are lost.
That is to say, if High-Resource Hospitals have notably different pa133. See id. at 656.
134. See id. at 659–60.
135. See Lucia A. Hindorff, et al., Prioritizing Diversity in Human Genomics Research,
19 NATURE REVS. GENETICS 175, 175 (2018) (“Increased attention to diversity will increase
the accuracy, utility and acceptability of using genomic information for clinical care.”).
136. See Alan H.B. Wu et al., The Hawaii Clopidogrel Lawsuit: The Possible Effect on
Clinical Laboratory Testing, 12 PERSONALIZED MED. 179, 179 (2015).
137. See id. at 180.
138. See Rachel Huddart et al., Are Randomized Controlled Trials Necessary to Establish
the Value of Implementing Pharmacogenomics in the Clinic?, 106 CLINICAL
PHARMACOLOGY & THERAPEUTICS 284, 285 (2019).
139. See Vence L. Bonham et al., Will Precision Medicine Move Us Beyond Race?, 374
NEW ENG. J. MED. 2003, 2004 (2016).
140. See, e.g., Margaret A. Hamburg & Francis S. Collins, The Path to Personalized
Medicine, 363 NEW. ENG. J. MED. 301, 301 (2010).
141. See, e.g., id.
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tient populations, then we should expect that medical AI trained on
data from those populations and then deployed in different settings
should encounter problems based on those patient population differences.
And in fact, at least some High-Resource Hospitals show substantially skewed patient populations. Roosa Tikkanen and her colleagues
found that white patients were three times as likely as black patients
to be admitted to academic medical centers in New York City in 2009,
controlling for insurance status, age, and gender. 142 Even after the
Affordable Care Act went into effect, the ratio was still more than two
to one.143 Thus, the data collected in those High-Resource Hospitals
would substantially underrepresent black patients. This pattern is not
universal among High-Resource Hospitals; Boston academic medical
centers did not show the same underrepresentation as in New York.144
Other studies have found similar results in terms of minority representation in academic medical centers.145
Genomic data provide a useful example of the underrepresentation of diverse populations in big health data. To be sure, genomic
data differ from electronic health records — EHRs are records of patient care that may be used for research, while genome sequences are
frequently generated specifically for research purposes. Nevertheless,
genomic data are key elements of big health data, especially those that
push boundaries to increase the precision of medicine, and are important for medical AI. And genomic sequence databases are tremendously non-representative. In 2009, 96% of participants in genomewide association studies were of European descent.146 More recently,
the diversity of those databases has increased — but almost exclusively because of increased genomic sequencing efforts by Asian cen-

142. Roosa Sofia Tikkanen et al., Hospital Payer and Racial/Ethnic Mix at Private Academic Medical Centers in Boston and New York City, 47 INT’L J. HEALTH SERVS. 460, 464
(2017).
143. Id.
144. See id. High-Resource Hospitals whose patient populations are more generally representative will tend to produce algorithms with fewer translational problems — at least on
the dimension of patient population differences.
145. See, e.g., Neil S. Calman et al., Separate and Unequal Care in New York City, 9 J.
HEALTH CARE L. & POL’Y 105, 107 (2006); Romana Hasnain-Wynia et al., Disparities in
Health Care Are Driven by Where Minority Patients Seek Care: Examination of the Hospital Quality Alliance Measures, 167 ARCHIVES INTERNAL MED. 1233, 1237–38 (2007);
Ashish K. Jha et al., The Characteristics and Performance of Hospitals that Care for Elderly Hispanic Americans, 27 HEALTH AFF. 528, 533–35 (2008).
146. See Anna C. Need & David B. Goldstein, Next Generation Disparities in Human
Genomics: Concerns and Remedies, 25 TRENDS GENETICS 489, 490 (2009).
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ters.147 Patients of Latin-American and African descent remain rare in
these databases.148
More generally, researchers are increasingly realizing that the data used to train medical AI are not representative of the populations in
which those AI may be used. Voice recognition AI often performs
poorly when analyzing accented voices.149 And the databases of skin
lesions used to train dermatological AI to recognize melanomas are
largely missing images from patients with darker skin.150
Overall, differences in patient populations may limit the generalizability of medical AI. Where AI is trained on data including only a
limited and non-representative set of patients, it will work less well
for patients outside that set. This problem has a familiar flavor; other
forms of medical intervention, such as drugs, are also developed in
particular patient contexts, and generalizability is an ongoing challenge.151 Some instances will matter more than others. It might be the
case that retinal images look pretty much the same from any population of patients in the world, so that contextual bias in retinal-imagebased diagnoses is a minimal concern — but skin images look very
different depending on whether the skin is fair or not. The problem
will vary, unsurprisingly, depending on the context.
But a second set of translational challenges also exists, more dependent on the pattern of medical AI’s development: challenges that
arise from the differences in resource capacity between HighResource Hospitals and other settings where black-box medical algorithms will be deployed.

147. See Alice B. Popejoy & Stephanie M. Fullerton, Genomics Is Failing on Diversity,
538 NATURE 161, 163 (2016).
148. See id. at 162. All of Us, the NIH-led initiative to obtain health records and genomic
sequences for more than a million Americans, is a notable effort to reflect patient diversity
and is discussed in detail below. See infra Section VI.C.
149. See Sonia Paul, Voice is the Next Big Platform, Unless You Have an Accent, WIRED,
(March 20, 2017, 12:00 AM), https://www.wired.com/2017/03/voice-is-the-next-bigplatform-unless-you-have-an-accent [https://perma.cc/9TXN-RBXH] (“AI can only recognize what it’s been trained to hear. Its flexibility depends on the diversity of the accents to
which it’s been introduced.”); see also Will Knight, AI Programs are Learning to Exclude
Some
African-American
Voices,
MIT
TECH. REV.
(Aug.
16,
2017),
https://www.technologyreview.com/s/608619/ai-programs-are-learning-to-exclude-someafrican-american-voices [https://perma.cc/M53G-PLCF] (noting similar problems for both
voice and text recognition).
150. See Adewole S. Adamson & Avery Smith, Machine Learning and Health Care Disparities in Dermatology, 154 JAMA DERMATOLOGY 1247, 1247 (2018).
151. For a small sampling of the extensive literature on pharmacogenomics, a field based
on this reality, see, for example, Mary V. Relling & William E. Evans, Pharmacogenomics
in the Clinic, 526 NATURE 343 (2015), and Simona Volpi et al., Research Directions in the
Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects,
103 CLINICAL PHARMACOLOGY & THERAPEUTICS 778 (2018).
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2. Resource Capacity Differences
A second major source of contextual bias occurs because differences in resources change which option is better — that is, which
treatment option an algorithm should recommend. This problem arises
with treatment recommendations in a way that it doesn’t with diagnostic expertise. When medical AI gives a particular diagnosis, it
simply provides that information, which is either accurate or not,
whatever the situation. Whether a patient actually has a subdural hematoma does not depend on whether the patient presents at Mass
General or in a rural Nigerian clinic. Whether AI gets that diagnosis
right may change based on the contexts of training and application.152
But the right diagnosis — the ground truth — does not change.
Treatment recommendations are different, because they need to be put
into practice — the provider and patient must actually undertake the
treatment, and that process differs in different contexts.153
Given a menu of treatment options for a given ailment, the “best”
or most appropriate option in a high-resource setting may well be
quite different than the best option in a low-resource setting. The most
straightforward version of this dichotomy is when recommended
treatment options are simply unavailable. In lower-resource settings,
patients and providers may not have access to machines necessary for
certain types of care (e.g., directed radiotherapy or laparoscopic surgery) or certain drugs, either because they are too expensive or because they require specific conditions for transport and storage. In the
very lowest-resource settings, drugs that require refrigeration may not
be available if reliable cold-chain transport is absent. But these types
of context disparities, while troubling, are at least easy to see; if AI
says to do X, but X isn’t possible, that’s an easy recommendation to
ignore. Algorithms with lots of those unhelpful recommendations
won’t improve care very much in lower-resource contexts, but at least
those algorithms won’t actively compromise care.
More problematically, some treatments work very well when performed by experts with excellent support structures, but poorly if performed without those resources. Algorithms trained in high-resource
settings may learn to prefer treatments that are only the best treatments when performed in those same high-resource settings. When
those algorithms are applied in lower-resource settings, lower-quality
care may result, and that drop in quality may be tough to observe.
Some examples may clarify the pattern.
Gallbladder cancer and inflamed gallbladders demonstrate the
tremendous difference in optimal choice based on the resources of the
152. See supra Section IV.A.1.
153. See supra Section II.C.2.
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medical setting.154 Gallbladder cancer is both extremely rare and extremely aggressive; if it metastasizes beyond the gallbladder, patients
have among the worse outcomes of any cancer. Cholecystitis, or inflammation of the gallbladder, on the other hand, is common. Cholecystitis is treated with a low-risk, technically straightforward surgery
wherein the surgeon laparoscopically removes the inflamed gallbladder. Often, though, a patient will present to a doctor with what appears
to be cholecystitis, but is actually gallbladder cancer. When that happens, the surgeon needs to notice — in the middle of the laparoscopic
surgery — the signs of likely cancer and then decide — again, midsurgery — whether to try to remove the cancer or stop the surgery and
send the patient to a higher-resource hospital. 155 Doing the surgery
(that is, removing the cancer and some surrounding tissue)
requires significantly more surgeon skill, as well as
surgeon education/understanding of the anatomy of
the liver, the gallbladder, and the blood vessels and
ducts. It also requires different, more specialized operative instruments. It will take longer, and it can be
much harder. But if it’s done correctly, the patient
has their appropriate, necessary cancer operation at
the time of (suspected) diagnoses. They may be
cured at that point, or they might need chemo, but it
gives them the best treatment and the best long-term
survival.
The problem with this option is that if there’s an error, the surgeon can seriously injure the liver itself,
the blood vessels and ducts to/from the liver, or,
much worse, tear the gallbladder and spill cancer
throughout the abdomen. Any of those has severe
consequences that will require significant resources
to address (or . . . advance the cancer and kill the patient).156
On the other hand, stopping the surgery and sending the patient to
a better-trained surgeon with better equipment has essentially no risk
(except the time elapsed), and no immediate benefit. Choosing to pur154. E-mail from Dr. Clare French, General Surgeon, SurgOne, P.C. (on file with author).
155. Not noticing the cancer is itself highly problematic (and a situation where AI could
help); if the surgeon does not notice the cancer, common techniques such as opening the
gallbladder to drain it before removal could be disastrous, spilling cancer throughout the
abdomen and dooming the patient to a rapid death. E-mail exchange with Dr. Clare French,
supra note 154.
156. Id.
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sue the surgery may well be the right option in a setting with trained
surgeons and better equipment — but is often a poor option in settings
without those resources.157 AI helping make that choice could easily
make the wrong choice if trained only in environments with highly
skilled surgeons.
Interventions do not have to be surgical. Choices among drugs
may also be resource-dependent. Consider the example of a chemotherapeutic raised above: while a powerful drug may be most efficacious against a cancer, it may also carry high risks of serious side
effects that require highly skilled monitoring to avoid. In a highresource setting, the stronger chemotherapeutic may be the right call;
outside such a setting, it may be catastrophic.
Overall, diagnostics and interventions that are the best options in
high-resource settings will frequently not be the best options in lowresource contexts. When black-box algorithms are trained exclusively
in high-resource settings, we should expect them to perform worse in
low-resource settings where both patient populations and available
resources are different.
B. Cost
Training medical AI in High-Resource Hospitals may also bias
the resulting algorithms toward selecting more costly procedures.
High-Resource Hospitals are on the cutting edge of medical treatment;
they are where the most sophisticated and up-to-date techniques and
technologies are developed and used. Academic medical centers also
tend to treat patients more intensively than do other medical settings.158 These treatments are often excellent — some researchers find
that academic medical centers do better by patients than other hospitals159 — but they are also more expensive.160
157. Nevertheless, surgeons in community hospitals certainly do sometimes think that attempting to remove the gallbladder cancer on the spot is the right option, and make that
choice — despite the higher risk and potential failure. Id.
158. See, e.g., Teryl Nuckols et al., What Value-Based Payment Means for Academic
Medical Centers, NEJM CATALYST (May 30, 2019), https://catalyst.nejm.org/value-basedpayment-academic-medical-centers [https://perma.cc/J8G4-T39Z].
159. See, e.g., Laura G. Burke et al., Association Between Teaching Status and Mortality
in US Hospitals, 317 JAMA 2105, 2107–10 (2017) (finding lower mortality rates at teaching hospitals for a range of common medical conditions, and finding that major teaching
hospitals did better than minor teaching hospitals); John Z. Ayanian & Joel S. Weissman,
Teaching Hospitals and Quality of Care: A Review of the Literature, 80 MILBANK Q. 569,
574–77 (2002) (reviewing the literature). But see Andrew M. Ibrahim et al., Association of
Hospital Critical Access Status with Surgical Outcomes and Expenditures Among Medicare
Beneficiaries, 315 JAMA 2095, 2096–99 (2016) (finding critical access rural hospitals
performed as well as noncritical access non-rural hospitals on common surgeries).
160. See, e.g., Lisa Rapaport, Teaching Hospitals in U.S. Are Expensive, But Have Lower
Death Rates, REUTERS (May 23, 2017 3:59 PM), https://www.reuters.com/article/us-healthhospitals-usa-mortality-idUSKBN18J2UG [https://perma.cc/6VZD-JED3]; Nuckols et al.,
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To the extent that providers in high-resource settings tend to
choose more intense, more costly interventions, medical AI will learn
those patterns and recommend them when translated to low-resource
settings. Such effects may develop over time. If an algorithm continually suggests that patients get PET scans, for instance, and a community hospital does not have a PET scanner, obviously the patient
cannot get that scan at that time. But providers in that hospital may
note the continued recommendations and push for the hospital to buy
a PET scanner to comport with the algorithm, resulting in higher costs
over time. Such higher costs may be warranted — perhaps the hospital really needs a PET scanner to provide appropriate care efficiently
and effectively. But in other cases, the AI may just suggest the more
expensive option because that option is more prevalent in highresource contexts, when a lower-cost option may be more appropriate
for the lower-resource context.
This pattern is likely to result in anti-frugal effects. Although
medical AI may reduce some costs — presumably, software is cheaper to run than an additional diagnostician is to hire — it may increase
other costs by systematically changing preferred patterns of care to
more closely match those at high-resource, more expensive care settings.161 Overall, translation between contexts looks to have problematic effects on both the quality of care and the cost of care.

V. ISN’T ALL MEDICINE CONTEXTUAL?
On being presented with these translational challenges, one might
ask: isn’t all medicine contextual anyway? That is to say, isn’t it the
case that all medicine depends on the particular patient in front of the
particular provider, the evidence upon which the intervention is based
and in what populations that evidence was developed, and the resources available to the provider in the immediate medical encounter? 162 This Part gives three replies to this question: first, even if
medical AI is just contextual like other medicine, that is worth noting;
second, the opacity of medical AI may hide contextual changes that
would otherwise be noticed; and third, the rhetoric and development
supra note 158. But see Laura G. Burke et al., Comparison of Costs of Care for Medicare
Patients Hospitalized in Teaching and Nonteaching Hospitals, JAMA NETWORK OPEN
(June 7, 2019), https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2735462
[https://perma.cc/M2EL-Y677] (presenting recent findings that indicate teaching hospitals
may not necessarily be as expensive as previously thought).
161. These increases in care complexity and intensity may have differential effects on
different patient populations, as well. Poorer patients are less able to undergo frequent follow-up visits, for instance, so a shift to more intensive follow-up care may disproportionately affect those patients.
162. In an even more direct comparison, doctors who work in low-resource contexts are
themselves typically trained in high-resource academic medical centers (that’s what makes
them academic medical centers). But they adapt their practice to their new contexts.
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of medical AI suggests that contextual dependence will not be a problem, making its existence more striking. The next Part addresses a
different set of issues, focusing on how medicine already deals with
contextual knowledge, and why those tools work less well for medical
AI.
First, even if the ultimate conclusion from this work is only that
medical AI is contextual like other types of medicine, and that its contextual effects may be concentrated across the gradient of resources,
that is worth knowing. Medical AI has the apparent promise of addressing contextual challenges in medicine by distributing expertise
and by taking account of patient variations to make care especially
precise — and hopefully, it will fulfill that promise! But unless the
status quo is changed, medical AI is subject to its own set of contextual biases. It is not an automatic panacea.
Second, opacity makes it potentially harder to spot problems that
may arise from contextual bias than to spot parallel problems in wellunderstood systems. Medical AI is black-box medicine; it is difficult
to know how it makes its recommendations.163 This opacity makes it
hard to spot the problems of contextual bias when they appear. If a
provider consults a Physician’s Desk Reference and sees that a particular treatment option is generally preferred but requires more resources to perform well than are available in a low-resource setting,
she can decide to pursue a less effective but more practical option. But
if this recommendation comes from an algorithm with no reasoning
given — it might be based on specific patient characteristics, or the
particulars of the diagnosis, or something else — it is harder to know
whether that recommendation or some alternative is the better
choice.164 Thus, medical AI’s contextual bias may be harder to understand and to rectify than in other medical situations.
Third and most importantly, the nature of machine-learning systems and the possibility of self-improvement provides an illusory
safety rail. This requires some unpacking. For other medical technologies, we recognize (or, at least, we’re starting to recognize) that the
technology is developed in a specific context and might not work so
well when deployed in other contexts. When the clinical trials used to
approve a drug include no pregnant women, we recognize — or
should — that evidence for its safe and effective use in pregnant
women is lacking.165 Perhaps more pointedly, whether or not the drug
works safely for pregnant women, we don’t expect the drug to change.
163. See, e.g., Price, Regulating Black-Box Medicine, supra note 98, at 429–31.
164. See, e.g., Jenna Burrell, How the Machine ‘Thinks’: Understanding Opacity in Machine Learning Algorithms, BIG DATA & SOC’Y, Jan.–June 2016, at 1, 1.
165. See Jeanne S. Sheffield et al., Designing Drug Trials: Considerations for Pregnant
Women, 59 CLINICAL INFECTIOUS DISEASES S437, S437 (2014) (supplement article) (“The
study of therapeutic agents in pregnant women has been virtually nonexistent for decades.”).
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But that’s not true for medical AI. Machine-learning systems hold out
the possibility of improvement; it’s right there in the name. Data from
deployment and use can be used to improve the algorithms so that
they get better over time.166 And so we might reasonably be more optimistic about context-specificity in medical AI: while the algorithm
isn’t perfect when it starts, it will learn from deployment contexts and
improve. But that safeguard is illusory. Contexts where medical AI is
likely to run into problems are precisely the contexts where we lack
the data needed to improve its performance: low-resource environments that lack the data infrastructure to train, improve, or even evaluate algorithms. 167 That lack of infrastructure doesn’t end with the
deployment of some black-box medicine implementations. Rather,
unless that deployment is embedded within new data infrastructure
that itself returns data to the algorithm’s development, we should expect that any contextual problems will remain unaddressed even as the
algorithm is used in the new context. Thus, medical AI holds out the
promise of improvement over time, but that promise will do little to
solve the problem of contextual bias in low-resource contexts.
So yes — all medicine is contextual, and black-box medicine is as
well. But given black-box medicine’s capacity for democratizing expertise, opacity, and capability for self-improvement in aspects other
than contextual bias, bias in black-box medicine demands special attention.

VI. SOLUTIONS
The problem of contextual bias in medical AI is likely to dampen
the potential benefits of democratizing medical expertise. Reducing
this problem will be tricky. This Part discusses several possible solutions and closes with a discussion of traps to avoid in implementing
them.
Two fairly obvious solutions for the quality problem both have
real challenges. First, for several reasons, “humans-in-the-loop” —
providers who can review and implement care options — won’t prevent the problems above, though they may sometimes ameliorate
them. Second, labeling of medical AI based on how and where it was
trained faces substantial difficulties in implementation, and even if it
works as intended, will not solve the problem.
Two quality solutions have more promise. First, public investment in data infrastructure can help tackle the problem at the front166. See Burrell, supra note 164, at 5; see also Ariel Bleicher, Demystifying the Black
Box that is AI, SCI. AM. (Aug. 9, 2017), https://www.scientificamerican.com/article/
demystifying-the-black-box-that-is-ai [https://perma.cc/3946-VCYY].
167. See supra Section III.A; see also Price, Risk and Resilience, supra note 32, at 74–
75.
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end by increasing the representativeness of data on which medical AI
is trained. Second, regulatory requirements of at least some evidence
of cross-contextual efficacy will reduce the incentives developers face
to develop medical AI only in high-resource contexts.
Cost is its own tremendous tangle of issues; I briefly discuss how
we might think through addressing it.
Finally, a coda considers three traps to avoid: too much contextualization, too little contextualization, and the innovation-stunting paralysis of the Nirvana fallacy.
A. Provider Safeguards and Humans-in-the-loop
Why doesn’t the presence of human providers in care settings resolve the concerns described above? Medical practice already incorporates variation between different contexts; different doctors have
different preferred strategies, and patients are different everywhere.
The way we tend to resolve this is by relying on providers at the point
of care to make the decision that is most appropriate for the patient in
front of them — the original version of “personalized medicine.” Why
doesn’t that work here to avoid these problems? I posit four reasons of
increasing force: (1) present provider ignorance; (2) reliance on algorithms; (3) future provider ignorance; and (4) provider absence. Each
reduces the force providers can bring to bear to correct translational
errors of medical AI — and, more generally, should decrease our confidence in relying on “human-in-the-loop” safety mechanisms for
medical AI.
1. Present Provider Ignorance
First, providers often don’t know what the best options are, and
therefore may not be suited to exercise independent corrective judgment on the decisions of algorithms. Famously, a large fraction of
medicine as practiced is not evidence-based. 168 Providers may not
know which option is preferable in general among a menu of options,
much less what treatment is preferable for the specific patient in front
of them or in the specific resource context of the medical encounter.
The examples from current practice listed above exemplify this pattern; it may be the wrong call to undertake surgical removal of
168. See, e.g., Diana Herrera-Perez et al., A Comprehensive Review of Randomized Clinical Trials in Three Medical Journals Reveals 396 Medical Reversals, ELIFE, June 11, 2019,
at 1, 5–12, https://doi.org/10.7554/eLife.45183.001 [https://perma.cc/WS22-LCSQ] (cataloging medical reversals); Kayte Spector-Bagdady et al., Stemming the Standard-of-Care
Sprawl: Clinician Self-Interest and the Case of Electronic Fetal Monitoring, 47 HASTINGS
CTR. REP. 16, 16–17 (2017) (describing the persistence of electronic fetal monitoring and
identifying the role of the legal system in that persistence).
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gallbladder cancer in low-resource settings, but some providers still
choose those options. Why would we assume that providers would
somehow acquire the knowledge to correct the errors of medical AI
when they currently make at least some similar errors in practice
without AI present?169
2. Reliance on Algorithms
Second, even if providers currently know what the ideal diagnostic or treatment pathway is, they may not actually exercise independent judgment when confronted with an algorithm providing a different
conclusion. Automation bias refers to a phenomenon where individuals rely on the results of automation even when they know or should
know that the automation is wrong.170 Sometimes, the individuals follow incorrect recommendations (commission errors), and sometimes
they fail to notice problems when the software does not flag them for
review (omission errors).171 Both types of errors have been observed
in the context of clinical decision support software in areas including
prescriptions, mammogram interpretation, EKG interpretation, and
clinical scenario management.172 Overall, we probably want at least
some level of automation bias, because good software still improves
the level of care, even if it occasionally makes mistakes.173 If providers are constantly second-guessing medical AI, we lose the benefits of
increased performance and efficiency that they promise.174 Nevertheless, the presence of automation bias decreases our ability to rely on
humans-in-the-loop to correct problems of medical AI, whether based
on problems with contextual translation or not.

169. In fact, sometimes this ignorance may lead to the opposite of the desired result: a
provider may override the correct decision of an algorithm because it does not accord with
her own knowledge or intuition, but that knowledge or intuition may be precisely wrong.
See Price, Medical Malpractice, supra note 106, at 296–98.
170. See David Lyell et al., Automation Bias in Electronic Prescribing, BMC MED.
INFORMATICS
DECISION
MAKING,
Mar.
16,
2017,
at
1,
1,
https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-017-0425-5
[https://perma.cc/Q3RL-JULR].
171. Id.
172. Id. at 1–2 (reviewing the literature and describing the results of a study on prescription automation bias).
173. Software that performs worse than humans is another story; avoiding software like
that is a big part of FDA’s role in this picture. See Price, Regulating Black-Box Medicine,
supra note 98, at 455–57.
174. See Andrew D. Selbst & Solon Barocas, The Intuitive Appeal of Explainable Machines, 87 FORDHAM L. REV. 1085, 1110 (2018); Price, Medical Malpractice, supra note
106, at 299–305.
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3. Future Provider Ignorance
Third, even if providers currently know enough to correct the errors of medical AI, that knowledge base may decrease over time as
medical AI becomes more commonplace. Michael Froomkin, Ian
Kerr, and Joelle Pineau have painted a picture of what might happen
to medical practice as medical AI becomes better and more available.175 They argue that as medical AI becomes more competent, doctors will be pushed to rely on it by, among other things, medical
malpractice, and that over time doctors will lose the knowledge necessary to practice medicine well and to know how well medical AI is
performing.176 One need not accept their argument wholesale to believe that as medical AI comes to perform at at-or-above human levels
on some medical tasks, and to be widely available, the incentives for
providers to train in those tasks will substantially decrease. This tendency will likely interact with the automation bias described immediately above, with the result that providers will be less able to catch
errors resulting from problems in medical AI.
4. Provider Absence
Fourth and finally, all the models of humans-in-the-loop to reduce
errors from medical AI, including contextual translation errors, rely
on humans actually being present to take their place in the loop. But
this is quite an assumption and will often be wrong. Consider again
the benefit of medical AI on which this work focuses: the possibility
of democratizing expertise, making high-level medical expertise
available to those who otherwise might not have it. When we assume
the presence of a skilled provider who can oversee the recommendations of medical AI, in a partnership rather than a replacement model,
and can correct errors of the sort discussed above, we assume away
this problem that medical AI can help us fix. Of course, a skilled surgeon can recognize the problems of trying to remove gallbladder cancer without the right operating tools, and could countermand the
recommendation of medical AI to proceed — but what about the
common situation where there is no skilled surgeon present? An excellent pathologist may recognize the mistakes of an AI-provided diagnosis of a particular pathology slide, but often there will be no
excellent pathologist available, especially in the type of lowerresource settings on which this work focuses.

175. See generally Froomkin et al., supra note 49 (describing changes to existing medical
liability rules to maintain physician participation and to avoid over-reliance on medical AI).
176. Id.; see also Federico Cabitza et al., Unintended Consequences of Machine Learning
in Medicine, 318 J. AM. MED. ASS’N 517, 517 (2017).
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In low-resource medical settings, we simply cannot assume the
presence of practitioners with the right set of knowledge to recognize
and fix the suboptimal recommendations medical AI may provide
when its insights translate poorly to that exact low-resource context.
Whether we are talking about community health centers, community
hospitals, solo practitioners, or rural health settings with very limited
provider availability, those settings will lack many types of expertise — and again, that’s precisely the point of medical AI.177 This is
not to say that human-in-the-loop is not a laudable model; there are
reasons to prefer rich provider involvement178 (though there are also
reasons to circumscribe that involvement179), and reasons to suspect
that in high-resource contexts skilled providers will be unwilling to
cede responsibility to medical AI.180 But relying on humans to catch
AI errors will not work in many contexts where medical AI promises
to do a tremendous amount of good.
B. Labeling
Labeling medical AI to provide more information to users provides a solution that is both obvious and problematic. It is obvious
because labeling is a common and straightforward way to recognize
the limitations of technology, especially medical technology. It is
problematic for three reasons. First, it is unclear how to label medical
AI appropriately to recognize the problem of contextual bias. Second,
providers often ignore medical labels and use technologies “offlabel.” Third, even if providers follow labeling restrictions about
where to use medical AI, such a path hobbles the goal of democratizing medical expertise.
Labeling could mean two distinct things in this context: the more
general labels that give instructions for any product, or FDAmandated labeling. Labels are familiar in many regulated contexts;181

177. See supra Section II.C.2.
178. See Kiel Brennan-Marquez & Stephen E. Henderson, Artificial Intelligence and
Role-Reversible Judgment, 109 J. CRIM. L. & CRIMINOLOGY 137, 146–48 (2019); Selbst &
Barocas, supra note 174, at 1138–39.
179. For instance, if providers consistently second-guess the recommendations of algorithms, and the algorithms perform at a higher level than the average provider, provider
reversal will on average lessen the quality of recommendations. See Price, Medical Malpractice, supra note 106, at 299–305 (discussing this dynamic); Selbst & Barocas, supra
note 174, at 1129.
180. Among other things, for the foreseeable future, providers are likely to bear ultimate
responsibility for final medical decisions. See Price, Medical Malpractice, supra note 106,
at 303. But see Cabitza et al., supra note 176, at 517 (noting provider willingness to defer to
algorithms).
181. See generally Omri Ben-Shahar & Carl E. Schneider, The Failure of Mandated Disclosure, 159 U. PA. L. REV. 647 (2011) (surveying mandatory disclosure regimes).
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cigarettes carry warnings about potential health risks182 and food carries labels stating nutrition content.183 Labeling relies on a combination of disclosure and choice: product users should be able to choose
how and whether to use a particular product, but they should be informed about the salient facts before making that choice (particularly
if those facts are hard for users to discern on their own).184
The FDA mandates its own specific form of labeling for products
it regulates, including drugs and medical devices — which as described above, will typically include medical AI.185 Labels for medical
devices must include adequate direction for use, including
“[s]tatements of all conditions, purposes, or uses for which such device is intended.”186 Use outside those conditions, just like for drugs,
is “off-label use.”187 The rest of this Section will assume the existence
of an FDA-approved label for medical AI as a medical device, but
similar arguments apply to non-FDA-approved labeling that just discloses information about a product to inform users.
Determining what information should go on a medical AI label
will be hard. Ideally, a label would provide enough information such
that those choosing to deploy it in a new context would know how
well to expect the algorithm to perform in that context, and what types
of failure or errors might be expected — and we don’t know that yet.
This Article has sought to open that conversation — mentioning,
among other things, patient composition and resource availability
(broadly defined) of the setting in which the algorithm was trained.
But to really know how to impose labeling requirements that contain
enough information to inform use meaningfully, we need to know a
lot more about the relevant sources of patient and provider variation

182. See, e.g., Kristin M. Sempeles, Note, The FDA’s Attempt to Scare the Smoke Out of
You: Has the FDA Gone Too Far with the Nine New Cigarette Warning Labels?, 117 PA.
ST. L. REV. 223, 232–35 (2012) (describing the labeling regime); see also Sara C. Hitchman
et al., Changes in Effectiveness of Cigarette Health Warnings Over Time in Canada and the
United States, 2002–2011, 16 NICOTINE & TOBACCO RES. 536, 536 (2013) (evaluating the
effectiveness of warning labels).
183. Nutrition Labeling and Education Act, Pub. L. No. 101-535, 104 Stat. 2353 (1990).
184. Ben-Shahar & Schneider, supra note 181, at 649–50.
185. See supra Section III.C.1.
186. 21 C.F.R. § 801.5 (2019); see also FDA, General Device Labeling Requirements,
https://www.fda.gov/medical-devices/device-labeling/general-device-labeling-requirements
[https://perma.cc/8U4W-SH69] (citing 21 C.F.R. § 801.5 (2019)).
187. See, e.g., Randall S. Stafford, Off-Label Use of Drugs and Medical Devices: A Review of Policy Implications, 91 CLINICAL PHARMACOLOGY & THERAPEUTICS 920, 920
(2012) (providing an overview of off-label use of drugs and devices); Jamie S. Sutherell et
al., Pediatric Interventional Cardiology in the United States is Dependent on the Off-Label
Use of Medical Devices, 5 CONGENITAL HEART DISEASE 2, 2–3 (2010) (finding that half of
all pediatric cardiac interventions involved an off-label use and that 99% of stent implantations were off-label).
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than we know now.188 This is not to say that such labeling is a futile
enterprise, but it will be difficult to get right.
More problematic is how labels are actually used or not used in
clinical care. In general, transparency is of limited efficacy in shaping
the use of technology, though it is a commonly-prescribed solution.189
Off-label use of drugs is famously common.190 Perhaps unsurprisingly, some of the most common off-label uses, such as pediatric use
without trials to support pediatric approval, 191 mimic common gaps in
health big data. And although drug labels rarely specify that they are
principally tested in relatively ancestrally homogeneous populations,
we might think of the widespread use of drugs or other treatments in
ancestral minorities in whom the treatments were not originally tested
as a sort of ersatz off-label use. So, too, we should expect that medical
AI would be used off-label just as other medical treatments are.192 If
an algorithm were trained in a relatively limited population, then using it in another population would be unsurprising — especially if the
algorithm otherwise seems to be a good tool, trained on data from
doctors in a high-resource setting.193
Third, finally, and most importantly: even if labels are welldesigned and even if providers actually follow them — that just gets
us back to the original problem. Recall the key goal of medical AI
that drives the issue of translation across contexts (and the rest of this
work): democratizing medical expertise, and allowing the provision of
excellent medical care in settings where it might otherwise be outside
the capabilities of providers in that setting. If labels state that medical
AI is developed in high-resource settings with relatively limited patient populations and should be limited to similar situations, and if
providers follow those labels to avoid using the medical AI in lowresource settings with different patient populations, then the medical
AI doesn’t actually democratize expertise at all. Respecting limita188. One parallel solution is to just let the algorithms sort all of this variation out, such
that rather than labels noting variation, the algorithms themselves take all relevant variation
into account. But this begs the question — that solution requires that algorithms be developed with enough data to see that range of variation, which by hypothesis throughout this
piece is not the case.
189. See, e.g., Ben-Shahar & Schneider, supra note 181, at 679. But see Ryan Bubb,
TMI? Why the Optimal Architecture of Disclosure Remains TBD, 113 MICH. L. REV. 1021,
1042 (2015) (arguing for the effectiveness of some disclosures).
190. See, e.g., Rebecca S. Eisenberg, The Problem of New Uses, 2 YALE J. HEALTH
POL’Y L. & ETHICS 717, 731 nn.62–63 (2005) [hereinafter Eisenberg, Problem of New
Uses].
191. See Sutherell et al., supra note 187, at 2–3.
192. One could imagine technological limitations built into algorithms, such that an algorithm trained only on adults, for instance, would simply not provide a recommendation in a
pediatric case. This would be challenging to implement and would also not solve the immediately following problem.
193. See supra Section III.B (describing the reputational benefit of training in highresource settings).
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tions of algorithmic development by avoiding potentially problematic
contexts is like responding to the problem of biased policing by keeping police out of minority neighborhoods entirely: it may decrease the
problem of bias, but it also loses any potential benefit that the technology or intervention might give to those in the second context.194
Labeling may still have some benefit. If, for instance, providers or
other purchasers of medical AI actually do follow restrictive labeling,
then developers would face incentives to demonstrate cross-context
efficacy to obtain a broader label and therefore broader use.195 But
this assumes that labels are closely followed, and also that the resources available in low-resource settings are sufficient to outweigh
incentives to focus development on high-resource settings — assumptions that are easy to challenge. On the other hand, training-based labels might be of more use when combined with two other
interventions: investment in data infrastructure and regulatory mandates for cross-context efficacy data.
C. Representative Datasets
A third way to ameliorate problems in contextual translation involves addressing the root of the issue: the initial training data. If the
existing dynamic is principally driven by data location — HighResource Hospitals are where the data are 196 — then policymakers
could push to generate and collect more data to change that initial
condition. The public — and by public, here I largely mean the government, whether state or federal197 — can invest in two types of data
infrastructure. 198 First, it can invest in infrastructure for data: resources like computer servers, personnel, standards, and procedures
that let data be collected, controlled for quality, and made available at
lower-resource settings such as community health centers.199 The public can also invest in the infrastructure of data: large collections of
194. See, e.g., Solon Barocas & Andrew D. Sebst, Big Data’s Disparate Impact, 104
CALIF. L. REV. 671, 689–90 (2016); I. Glenn Cohen & Harry S. Graver, Cops, Docs, and
Code: A Dialogue Between Big Data in Health Care and Predictive Policing, 51 U.C.
DAVIS L. REV. 437, 443–44 (2018).
195. See Eisenberg, Problem of New Uses, supra note 190, at 734–35.
196. See supra Section III.A.
197. Private investors could also invest in funding such data infrastructure, but private
investment in infrastructure tends to be socially suboptimal because private actors cannot
adequately capture the spillover benefits that infrastructural goods provide for other innovators and downstream users. See BRETT M. FRISCHMANN, INFRASTRUCTURE: THE SOCIAL
VALUE OF SHARED RESOURCES 66 (2012); Price, Risk and Resilience, supra note 32, at 77–
78. Private firms also have incentives to keep data collected as trade secrets to maintain
competitive advantage, which causes problems both for data aggregation across firms and
for external validation of medical AI models. See Price, Big Data, supra note 71, at 1432–
35.
198. Price, Risk and Resilience, supra note 32, at 78–79.
199. Id.
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data that can enable broad sets of future innovation and economic activity, such as developing black-box medical algorithms.200
Investing in infrastructure for data could take several forms. Most
obviously, grants specifically directed to support the purchase of
computer systems or the hiring of data personnel could ameliorate the
data acquisition problem of low-resource settings.201 Less obviously,
governments can set standards, which themselves are a sort of infrastructure. Electronic health records currently use a hodgepodge of
formats due to an early decision not to federally mandate a centralized
format; this situation has resulted in problems of interoperability and
data fragmentation.202 The federal government is moving to address
interoperability problems, but could and probably should go further to
require standards for electronic health records.203 Government efforts
could also ease the burden of developing data infrastructure: adding a
research exemption to the HIPAA Privacy Rule, for instance, would
make it easier for low-resource settings to collect data by removing
one set of legal concerns.204
The advantage of public funding of infrastructure for and of data,
whether through grant funding or direct spending, is that such infrastructure does not have to follow the pre-existing patterns of what is
collected and where. Instead, data collected through a public infrastructure effort can better represent the care that many patients actually experience. 205 If high-quality data are collected about a wide
variety of patients, the concerns about effects from different patient
populations decrease.206 And if data are collected about a wider range
of care settings — not just High-Resource Hospitals, but community
hospitals, community health centers, practitioner’s offices, and the
like — those data can more accurately reflect the resources available
in the care setting, the range of practices followed, the types of treatment implemented, and the outcomes that result.207
200. Id.; see also Price, Big Data, supra note 71, at 1439–44 (proposing an infrastructure
model for gathering data to promote the development of black-box medical algorithms);
MATHENY ET AL., supra note 4, at 169–71 (arguing that, for medical AI to reach its potential, datasets must be conceptualized as a “public good”).
201. Even here, there may be backlash along the lines of, “Why fund data when we have
insufficient funding for care?” The awkward answer is that better, broader data make future
care better and cheaper — but that may be a difficult sell to those facing resource gaps.
202. Julia Adler-Milstein, Moving Past the EHR Interoperability Blame Game, NEJM
CATALYST (July 18, 2017), http://catalyst.nejm.org/ehr-interoperability-blame-game
[https://perma.cc/BPT7-4SLM].
203. Id.
204. See Price, Drug Approval, supra note 77, at 2460–61. In fact, an earlier draft of the
21st Century Cures Act included such a provision, but it was removed in the final text. Id.
205. Indeed, grant funding involving data collection could be conditioned on a requirement that data be more representative.
206. See supra Section IV.A.1.
207. This data collection goal is essential to the development of a learning health system
more broadly. See Elizabeth A. McGlynn et al., Developing a Data Infrastructure for a

No. 1]

Medical AI and Contextual Bias

109

The difficulty of this endeavor should also not be minimized.
There are reasons that data collection practices today are as they
are.208 Gathering data well is hard and can be expensive.209 Privacy
concerns are also implicated in the gathering, use, and sharing of large
amounts of sensitive health data.210 Nevertheless, investment in those
data-gathering capacities — across many contexts — is likely to pay
substantial dividends down the line, including in those same lowresource contexts.
The NIH’s All of Us initiative is a prominent example of exactly
this type of infrastructural investment in data.211 All of Us (formerly
the Precision Medicine Cohort) is a part of the Precision Medicine
Initiative. 212 Through All of Us, the NIH plans to gather detailed
health information — including genetic sequences, treatment information, and outcome data — from over one million Americans. Crucially, the sample population for All of Us is meant to be nationally
representative. 213 According to Francis Collins, the Director of the
NIH, the program has a goal that half of its participants come from
traditionally underrepresented groups.214 If the definition of diversity
is broadened to include socioeconomic status and rural status, then the
Learning Health System: The PORTAL Network, 21 J. AM. INFORMATICS ASS’N 596, 598–
600 (2014). Increased data infrastructure also allows other types of innovation and measurements of health system quality more generally. Id.
208. See supra Section III.A.
209. Id. Secondary questions also arise as to the best allocation of resources. One might
argue that any new resources allocated to low-resource medical contexts should be aimed
directly at improving care rather than improving data infrastructure. That calculus is complex. I argue here only that investment in data infrastructure in low-resource contexts will
benefit patients in those contexts down the road, not that such investment is the best use of
scarce resources. However, infrastructure is often a useful investment, considering the
amount by which it can increase innovation and future welfare. See, e.g., W. Nicholson
Price II, Grants, 34 BERKELEY TECH. L.J. 1, 59 (2019) (discussing the role of government
grants in providing infrastructure for future innovation).
210. I have examined the privacy concerns of medical big data and medical AI in some
detail elsewhere. See Roger Allan Ford & W. Nicholson Price II, Privacy and Accountability in Black-Box Medicine, 23 MICH. TELECOMM. & TECH. L. REV. 1, 19–20 (2016) (discussing the privacy challenges of medical AI in general and noting the tension between
third-party validation and privacy protections); Price, Drug Approval, supra note 77, at
2458 (describing the limitations HIPAA and other privacy rules place on the innovation of a
learning health system where patient data are constantly used to improve medical
knowledge); W. Nicholson Price II & I. Glenn Cohen, Privacy in the Age of Medical Big
Data, 25 NATURE MED. 37, 42 (2019) (surveying the privacy landscape for medical big data
and arguing against a “privacy maximalist” approach).
211. See NAT’L INST. OF HEALTH, All of Us Research Program, https://allofus.nih.gov
[https://perma.cc/T2B9-6Z3D]. Other examples include the UK Biobank. See Editorial, UK
Biobank Data on 500,000 People Paves Way to Precision Medicine, NATURE (Oct. 10,
2018), https://www.nature.com/articles/d41586-018-06950-9 [https://perma.cc/WK9UGJZW].
212. NAT’L INST. OF HEALTH, supra note 211.
213. Id.
214 Francis Collins, Keynote: An Update on All of Us, PROC. PRECISION MED. WORLD
CONF. (June 6, 2018).
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NIH plans to draw 75% of participants from diverse groups more generally.215 This goal speaks directly to diversity and representativeness
of patient population, and at least indirectly to the diversity of medical
contexts, given that many of these participants are likely to seek medical care in low-resource contexts.216 Efforts like All of Us should be
supported, continued, and expanded.
To be clear, more representative datasets do not need to be publicly funded. The dynamics described in Part III make nonrepresentative data an easy default for private parties, but private parties could also seek to address it (especially if required to as described
immediately below). One approach could blend private spending on
infrastructure for data with private acquisition of data. If developers
sought data from low-resource contexts but recognized that those contexts lacked the resources to generate high-quality data, those developers could themselves provide the resources — technological or
personnel-based — in exchange for access to the data generated,
which would then fuel better performance down the road.
D. FDA Regulation and Concordance
The FDA could also play a role in decreasing problems of contextual translation. As described above, the reliance on data from HighResource Hospitals may be over-determined: not only are data currently found in high-resource contexts, but using data from those contexts also helps avoid risks arising from FDA regulation, tort liability,
and insurance reimbursement pathways. To help reduce these pressures to focus medical AI training on data from a limited set of medical contexts, the FDA approval process for medical AI products could
be shifted to require explicit concordance data and demonstration of
cross-context performance.
The FDA could explicitly require that developers seeking clearance or approval for medical devices using AI or machine learning
include concordance data demonstrating performance in contexts outside the original development context.217 More specifically, if an algorithm proposes to recommend treatment pathways based on patient
characteristics, FDA could require that the validation of those pathways consider not only the high-resource contexts where the algo-

215. Id.
216. See supra Section IV.A.1.
217. The FDA could implement such requirements for other technology, including other
algorithms; however, as described in this Article, black-box algorithms are particularly
worrisome and therefore merit special attention.
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rithm was developed but also low-resource contexts where it is likely
to be deployed.218
A requirement for low-resource concordance demonstrations
would not be trivial. In the current state of the world, low-resource
contexts will often have insufficient data to allow purely data-based
validation. 219 Thus, demonstrating concordance now might require
extra clinical trials, which are costly and don’t always match well
with the development of black-box medicine. 220 Implementation of
better data infrastructure — ideally, of a data-based learning health
system more broadly — should eventually decrease the difficulty of
validation of performance in different environments.221 The near term
is likely to be messy. But FDA requirements and infrastructural investments could interact in a self-sustaining cycle: infrastructural investments in data can help support the ability to demonstrate
concordance to FDA, while FDA requirements to demonstrate concordance would encourage data infrastructure investment.
While FDA requirements for concordance would be unusual, such
requirements have some precedent. The FDA already encourages
greater gender, racial, and ethnic diversity among clinical trial participants, though it does not require it.222 Clinical research funded by the
NIH has even stronger diversity requirements; in 1993, Congress
passed the National Institutes of Health Revitalization Act, which required the NIH Director to ensure inclusion of women and minorities
in clinical research. 223 These requirements are not squarely on
point — the NIH policy stems from grant funding of clinical trials,
and FDA encouragement is voluntary — but they demonstrate a similar commitment to ensuring that clinical trials show that treatments
work in different groups.

218. See, e.g., Performance, supra note 43, at 4–5 (describing clinical trial testing IDxDR in ten primary care clinics across the United States).
219. See supra Section III.A; see also Ford & Price, supra note 210, at 18–21 (2016)
(discussing the idea of data-based validation); Price, Regulating Black-Box Medicine, supra
note 98, at 432–37 (same).
220. See Price, Regulating Black-Box Medicine, supra note 98, at 434–35.
221. This infrastructure, as described above, would also weaken the primary motivator
for focus on High-Resource Hospitals, their predominance in possessing relevant data. See
supra Section VI.C.
222. FDA, FDA Encourages More Participation, Diversity in Clinical Trials (Jan. 16,
2018),
https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm535306.htm
[https://perma.cc/V24R-8TN2]; FDA, Racial and Ethical Minorities in Clinical Trials (Aug.
6, 2018), https://www.fda.gov/forconsumers/byaudience/minorityhealth/ucm472295.htm
[https://perma.cc/QVT7-3A68].
223. Pub. L. No. 103-43, § 131, 107 Stat. 122, 133–35 (1993) (codified at 42 U.S.C.
§ 492B (1988)); see also NAT’L INST. OF HEALTH, NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research (Oct. 9, 2001),
https://grants.nih.gov/grants/funding/women_min/guidelines.htm [https://perma.cc/QVT73A68].
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FDA involvement in demonstrating concordance and applicability
across contexts could also help resolve the other two legal incentives
currently pushing for development based on high-resource data: tort
liability and insurance reimbursement.224 When FDA approves a medical device as a Class III device (i.e., a higher-risk device) under its
premarket approval pathway, state tort liability is largely preempted
for that device under Riegel v. Medtronic.225 Thus, at least for companies that pursue Class III premarket approvals — and assuming that
concordance data helps persuade FDA to grant such approvals — tort
liability concerns should also largely be resolved by that process.226
This doesn’t resolve all liability concerns. Bringing a device to market
through the 510(k) preclearance pathway (i.e., a finding that the device has an already-approved predicate device on the market) does not
preempt state tort lawsuits,227 and so far developers have been able to
use that pathway (or de novo classification228) and to bring devices to
market as Class I or Class II devices rather than undergoing the costlier premarket approval pathway for Class III devices.229
Finally, FDA approval, especially if that process includes concordance data, should help resolve issues of insurer reimbursement.
As described above, FDA approval and CMS reimbursement decisions are frequently linked, 230 and private payers frequently follow
CMS’s lead. 231 An FDA-approved demonstration that an algorithm
works in different contexts could similarly support payer determinations that the technology is worth reimbursing across those different
contexts, even in the absence of the current quality proxy of training
224. See supra Sections III.C.2–3.
225. See Riegel v. Medtronic, Inc., 552 U.S. 312, 345 (2008).
226. This analysis assumes that Riegel’s bright-line rule — Class III premarket approval
preempts state tort suits — remains. The possibility of medical AI changing over time with
new data might suggest that this rule should be revisited because a prior approval might no
longer serve as evidence of current safety in the same way as for a relatively static medical
device.
227. See Medtronic, Inc. v. Lohr, 518 U.S. 470, 471 (1996).
228. As far as I know, no court has yet determined whether a determination by FDA under the de novo pathway that a device is Class II is sufficient to preempt state tort liability.
Predicting the result is outside the scope of this work.
229. See supra notes 99–101. I have argued elsewhere that a rigid premarket approval
process is likely to stifle innovation in black-box medicine. Price, Regulating Black-Box
Medicine, supra note 98, at 451–54. The FDA is currently engaged in efforts to ease the
path to market for digital health generally, including medical AI.
See FDA, Digital Health Innovation Action Plan, https://www.fda.gov/downloads/
MedicalDevices/DigitalHealth/UCM568735.pdf [https://perma.cc/ZLP9-G77U]. It remains
to be seen how much FDA’s efforts at more flexible market pathways will end up making
premarket approval itself a more attractive option for developers. See Eisenberg, Device
Regulation, supra note 117 (discussing this dynamic in the context of diagnostics more
generally).
230. See supra Section III.C.3; see also Sachs, Delinking Reimbursement, supra note
114, at 2311.
231. Eisenberg & Price, supra note 80, at 31–32.
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on data from high-resource medical contexts. Such FDA approval
incentives could be even stronger if reimbursement is greater for devices that go through full premarket approval rather than 510(k) clearance — a difference that CMS currently is pressing.232
FDA approval modifications will not be a panacea, of course; insurers may still prefer the cachet of high-resource settings and developers may also seek the prima facie liability reduction that could
come with name-brand training data. Persuading providers and health
systems to adopt black-box medical systems may also still be easier
while partnering prominently with High-Resource Hospitals. 233 But
linking FDA approval, with its concomitant benefits, to a development process that at least attempts to ensure validity across contextual
translation may help ease the path to broadly useful medical AI.
E. Incorporating Cost
The cost problem is extremely tough. As described above, algorithms that learn about the right kind of care in high-resource settings
may simultaneously learn that the right kind of care is an expensive
form of care, with many interventions and fancy, costly tools.234 This
may sometimes even be correct; sometimes, high-intervention care is
the right way to go, and some costly interventions rightly spread from
high-resource contexts to low-resource contexts. But it also creates
the possibility for AI acting as a vector in increasing costs in a system
which sorely needs to reduce costs, and in which AI has at least the
potential to contribute to that reduction.235
A potential solution is easy to state but hard to implement. The
most straightforward way for AI algorithms to address cost issues
would be to add those issues to the AI’s optimization function: that is,
when scoring outcomes as desirable or undesirable (for the purposes
of care recommendations, at least), the cost of care could be included
in the score, rather than just patient health measures. Algorithms
would then prioritize not simply outcomes or duplicating the patterns
prevalent in High-Resource Hospitals, but also cost-effectiveness.
Implementing such measures could be quite challenging, especially since in the U.S. rationing health dollars is a hot-button issue.236
And, at least in a fee-for-service system, which still exists in many
contexts, provider and health system incentives typically push for
more care, and costlier care, rather than efficient and cost-effective
232. See CTRS. MEDICARE & MEDICAID SERVS., supra note 119 and accompanying text.
233. See supra Section III.C.3.
234. See supra Section IV.B.
235. Id.
236. See, e.g., Elizabeth Weeks Leonard, Death Panels and the Rhetoric of Rationing, 13
NEV. L.J. 872, 873–74, 886 (2013).
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care. It seems more likely that the first medical AI systems focused on
cost will aim to promote revenue maximization rather than efficiency.237 But building costs into the initial models could eventually help
some AI systems reduce system costs, assuming that cost reduction
becomes a goal of system developers.
F. Traps to Avoid
Figuring out how best to develop and to deploy AI to democratize
medical expertise is hard. It’s made harder because contextual bias is
not the only challenge that medical AI faces. If we try too hard to
eliminate contextual bias, we could wind up with any of three related
problems: too much contextualization, insufficient contextualization,
or inadequate adoption.238
First, pushing too hard to ensure that AI is trained for each context could result in too much contextualization. One potential solution
to the problem of contextual bias is to train AI in a wide variety of
contexts so that every context has its own AI matched specifically to
it. But the health system is rife with disparity, and AI might replicate
or enhance those disparities.239 Not only do many low-resource contexts lack the capacity to generate the data to train medical AI, or to
support the training and validation necessary once those data are gathered, any AI that might result would be trained on a context with, by
definition, a lack of resource-based expertise. Medical AI trained in
health centers in rural India would avoid any problems of contextual
bias when translated to other rural Indian health centers (or perhaps to
other developing-world rural health centers), but it would lack the
benefit of being trained on providers with the most extensive training,
tools, and experience in high-resource settings. Such an approach
would democratize only limited forms of medical expertise and would
leave much of the benefit of medical AI on the table.240

237. AI developed by payers, on the other hand, might prioritize efficiency. See Eisenberg & Price, supra note 80, at 16–18.
238. A separate and complex set of issues concerns the distributional effects of efforts to
ensure broad applicability — why not just allow medical AI to be developed for those in
high-resource contexts, and perhaps those benefits will eventually trickle down to those in
low-resource contexts? One preliminary answer might be that to the extent that medical AI
is touted for its benefit in democratizing expertise, this Article takes that goal as a given and
focuses on how to actually achieve it successfully. Other answers about the ideal path for
development and spread of new technology more generally are outside the scope of this
work.
239. See, e.g., Khullar, supra note 130; Charlotte A. Tschider, Regulating the Internet of
Things: Discrimination, Privacy, and Cybersecurity in the Artificial Intelligence Age, 96
DENV. U. L. REV. 87, 98–100 (2018) (describing concerns of AI systems codifying existing
disparities).
240. See, e.g., Alvin Rajkomar et al., Ensuring Fairness in Machine Learning to Advance
Health Equity, 169 ANNALS INTERNAL MED. 866, 866–868 (2018).
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Second, trying to avoid variation in algorithmic performance in
different contexts could result in too little contextualization. In an ideal world, medical AI would be able to take advantage of differences in
resources. If a hospital has a top-notch PET scanner and very experienced surgeons, AI algorithms that make recommendations should
consider those options within the set of possibilities. In an ideal world,
everyone would have access to the best care, but that is not our world,
and not all hospitals have such resources. We don’t want medical AI
never to suggest using a PET scanner or undertaking a risky surgery
just because those are unhelpful or actively harmful suggestions in
some medical contexts. And patient populations do differ, both as
groups and as individuals; medical AI should be able to take account
of those differences as well.241 Part of the appeal of black-box medicine is the possibility of intensely personalized analysis and recommendations for care; requiring too stringent replicability across
contexts might sacrifice some of that precision. Those designing concordance policies need to tread a middle path.
Third, focusing too much on these problems — contextual bias,
too much contextualization, and insufficient contextualization —
could result in decisionmakers throwing up their hands and avoiding
the new problems that come with medical AI, preferring the status
quo. This is the Nirvana fallacy, where new options are compared to
perfection rather than a flawed status quo.242 But the status quo itself
already has lots of problems, some of which form the impetus for
medical AI in the first place.243 The promise of democratizing expertise is enticing precisely because we have too few experts, and many
patients face barriers to accessing high-quality care in all but the highest-resource settings. Avoiding the adoption of medical AI because it
might not work as well in low-resource contexts does nothing to aid
patients who already lack options because of the lack of resources.244
Ultimately, even flawed medical AI may prove transformative for
millions of patients, and we should endeavor to see that promise even
while we try to avoid the pitfalls of cross-context translation.

VII. CONCLUSION
Medical AI has tremendous promise to bring excellent medical
care to those that might not otherwise see such care. Translating
241. See Price, Black-Box Medicine, supra note 2, at 425–30.
242. Demsetz, supra note 13, at 1.
243. See Price, Black-Box Medicine, supra note 2, at 434–37.
244. Adoption of medical AI is already likely to face barriers from providers and potentially patients; too much focus on contextual bias is likely to increase already-existing hurdles. See, e.g., Price, Black-Box Medicine, supra note 2, at 437–42 (discussing barriers to
adoption).
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black-box algorithms from high-resource contexts to low-resource
contexts, though, brings the risk of problems; what works well in one
context may not in another. If we are to avoid the risks of compromising care for those in low-resource settings, now is the time to consider
how medical AI can be developed not just for those who already have
access to excellent care, but for those who can benefit most from the
advent of this new technology.

